BRPI0713216A2 - inibiadores heterocìclos fundidos da d-aminoácido oxidase - Google Patents

Info

Publication number

BRPI0713216A2

BRPI0713216A2 BRPI0713216-6A BRPI0713216A BRPI0713216A2 BR PI0713216 A2 BRPI0713216 A2 BR PI0713216A2 BR PI0713216 A BRPI0713216 A BR PI0713216A BR PI0713216 A2 BRPI0713216 A2 BR PI0713216A2

Authority

BR

Brazil

Prior art keywords

substituted

unsubstituted

formula

alkyl

heterocycloalkyl

Prior art date

2006-06-30

Links

• Espacenet
• Global Dossier
• Discuss

• 108010003989 D-amino-acid oxidase Proteins 0.000 title claims abstract description 53
• 239000003112 inhibitor Substances 0.000 title claims abstract description 37
• 102000004674 D-amino-acid oxidase Human genes 0.000 title claims abstract 22
• 125000000623 heterocyclic group Chemical group 0.000 title claims description 13
• 150000001875 compounds Chemical class 0.000 claims abstract description 301
• 208000002193 Pain Diseases 0.000 claims abstract description 105
• 229910052717 sulfur Inorganic materials 0.000 claims abstract description 64
• 229910052757 nitrogen Inorganic materials 0.000 claims abstract description 29
• 229910052760 oxygen Inorganic materials 0.000 claims abstract description 28
• 208000015122 neurodegenerative disease Diseases 0.000 claims abstract description 19
• 230000004770 neurodegeneration Effects 0.000 claims abstract description 17
• 208000012902 Nervous system disease Diseases 0.000 claims abstract description 15
• 206010010904 Convulsion Diseases 0.000 claims abstract description 13
• 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 10
• 206010003591 Ataxia Diseases 0.000 claims abstract description 9
• -1 (II) CN Inorganic materials 0.000 claims description 118
• 125000000217 alkyl group Chemical group 0.000 claims description 115
• 125000003118 aryl group Chemical group 0.000 claims description 91
• 125000001072 heteroaryl group Chemical group 0.000 claims description 88
• 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 85
• 150000002500 ions Chemical class 0.000 claims description 68
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 65
• 229910052739 hydrogen Inorganic materials 0.000 claims description 62
• 125000004404 heteroalkyl group Chemical group 0.000 claims description 59
• 229910052731 fluorine Inorganic materials 0.000 claims description 53
• 125000000753 cycloalkyl group Chemical group 0.000 claims description 52
• 229910052794 bromium Inorganic materials 0.000 claims description 46
• 229910052801 chlorine Inorganic materials 0.000 claims description 46
• 229930195711 D-Serine Natural products 0.000 claims description 43
• MTCFGRXMJLQNBG-UWTATZPHSA-N D-Serine Chemical compound OC[C@@H](N)C(O)=O MTCFGRXMJLQNBG-UWTATZPHSA-N 0.000 claims description 40
• 208000004296 neuralgia Diseases 0.000 claims description 37
• 208000021722 neuropathic pain Diseases 0.000 claims description 36
• 150000003839 salts Chemical class 0.000 claims description 32
• 125000003710 aryl alkyl group Chemical group 0.000 claims description 31
• 229910052727 yttrium Inorganic materials 0.000 claims description 29
• 125000002252 acyl group Chemical group 0.000 claims description 27
• 125000004429 atom Chemical group 0.000 claims description 24
• 125000004446 heteroarylalkyl group Chemical group 0.000 claims description 23
• 229910052736 halogen Inorganic materials 0.000 claims description 22
• 201000010099 disease Diseases 0.000 claims description 21
• 239000000651 prodrug Substances 0.000 claims description 21
• 229940002612 prodrug Drugs 0.000 claims description 21
• 229910052799 carbon Inorganic materials 0.000 claims description 20
• 201000000980 schizophrenia Diseases 0.000 claims description 20
• 125000003342 alkenyl group Chemical group 0.000 claims description 18
• 208000024827 Alzheimer disease Diseases 0.000 claims description 17
• 150000002367 halogens Chemical class 0.000 claims description 17
• 230000019771 cognition Effects 0.000 claims description 16
• 208000000044 Amnesia Diseases 0.000 claims description 14
• 208000026139 Memory disease Diseases 0.000 claims description 14
• HOKKHZGPKSLGJE-GSVOUGTGSA-N N-Methyl-D-aspartic acid Chemical compound CN[C@@H](C(O)=O)CC(O)=O HOKKHZGPKSLGJE-GSVOUGTGSA-N 0.000 claims description 11
• 125000005842 heteroatom Chemical group 0.000 claims description 11
• 125000004433 nitrogen atom Chemical group N* 0.000 claims description 11
• 239000003937 drug carrier Substances 0.000 claims description 10
• 230000006984 memory degeneration Effects 0.000 claims description 10
• 208000023060 memory loss Diseases 0.000 claims description 10
• 208000030507 AIDS Diseases 0.000 claims description 9
• 125000004122 cyclic group Chemical group 0.000 claims description 9
• OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 8
• 206010036376 Postherpetic Neuralgia Diseases 0.000 claims description 8
• 208000032131 Diabetic Neuropathies Diseases 0.000 claims description 7
• 208000023890 Complex Regional Pain Syndromes Diseases 0.000 claims description 6
• 125000003545 alkoxy group Chemical group 0.000 claims description 6
• 125000005647 linker group Chemical group 0.000 claims description 6
• 150000008569 D-serines Chemical class 0.000 claims description 5
• 208000001640 Fibromyalgia Diseases 0.000 claims description 5
• 208000018737 Parkinson disease Diseases 0.000 claims description 5
• 230000002981 neuropathic effect Effects 0.000 claims description 5
• 206010044652 trigeminal neuralgia Diseases 0.000 claims description 5
• CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 claims description 4
• 150000001721 carbon Chemical group 0.000 claims description 4
• 239000002243 precursor Substances 0.000 claims description 4
• 125000003107 substituted aryl group Chemical group 0.000 claims description 4
• 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 3
• DYDCUQKUCUHJBH-UWTATZPHSA-N D-Cycloserine Chemical compound N[C@@H]1CONC1=O DYDCUQKUCUHJBH-UWTATZPHSA-N 0.000 claims description 3
• DYDCUQKUCUHJBH-UHFFFAOYSA-N D-Cycloserine Natural products NC1CONC1=O DYDCUQKUCUHJBH-UHFFFAOYSA-N 0.000 claims description 3
• 210000000278 spinal cord Anatomy 0.000 claims description 3
• 230000005062 synaptic transmission Effects 0.000 claims description 3
• 206010058019 Cancer Pain Diseases 0.000 claims description 2
• 150000008574 D-amino acids Chemical class 0.000 claims description 2
• 208000008930 Low Back Pain Diseases 0.000 claims description 2
• 208000004983 Phantom Limb Diseases 0.000 claims description 2
• 206010056238 Phantom pain Diseases 0.000 claims description 2
• 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims description 2
• 206010027599 migraine Diseases 0.000 claims description 2
• 238000011260 co-administration Methods 0.000 claims 1
• 150000004677 hydrates Chemical class 0.000 claims 1
• 238000000034 method Methods 0.000 abstract description 121
• 238000011282 treatment Methods 0.000 abstract description 37
• 230000002265 prevention Effects 0.000 abstract description 7
• 208000025966 Neurological disease Diseases 0.000 abstract description 6
• XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 294
• IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 230
• 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 194
• 230000015572 biosynthetic process Effects 0.000 description 156
• 238000003786 synthesis reaction Methods 0.000 description 153
• HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 140
• 238000005160 1H NMR spectroscopy Methods 0.000 description 131
• OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 124
• YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 90
• 239000000203 mixture Substances 0.000 description 87
• 238000005481 NMR spectroscopy Methods 0.000 description 85
• 239000007787 solid Substances 0.000 description 73
• HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 72
• OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 70
• LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 68
• 239000000460 chlorine Substances 0.000 description 67
• 239000000243 solution Substances 0.000 description 67
• WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 62
• VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 53
• 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 51
• 238000003818 flash chromatography Methods 0.000 description 50
• 238000006243 chemical reaction Methods 0.000 description 49
• 238000004128 high performance liquid chromatography Methods 0.000 description 46
• 238000000746 purification Methods 0.000 description 46
• 238000010898 silica gel chromatography Methods 0.000 description 46
• XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 45
• 208000035475 disorder Diseases 0.000 description 44
• VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 42
• 239000002253 acid Substances 0.000 description 41
• WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 39
• 239000011734 sodium Substances 0.000 description 39
• RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 38
• 150000001732 carboxylic acid derivatives Chemical class 0.000 description 36
• 230000000694 effects Effects 0.000 description 36
• 230000015654 memory Effects 0.000 description 34
• 238000010992 reflux Methods 0.000 description 34
• NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 33
• YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical compound C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 33
• IVSZLXZYQVIEFR-UHFFFAOYSA-N m-xylene Chemical group CC1=CC=CC(C)=C1 IVSZLXZYQVIEFR-UHFFFAOYSA-N 0.000 description 32
• KDLHZDBZIXYQEI-UHFFFAOYSA-N palladium Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 32
• 239000000047 product Substances 0.000 description 31
• 239000000741 silica gel Substances 0.000 description 30
• 229910002027 silica gel Inorganic materials 0.000 description 30
• 125000001424 substituent group Chemical group 0.000 description 30
• RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 29
• 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 29
• 230000013016 learning Effects 0.000 description 29
• 150000007942 carboxylates Chemical class 0.000 description 28
• 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 27
• 102100026908 D-amino-acid oxidase Human genes 0.000 description 25
• ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 24
• 239000011541 reaction mixture Substances 0.000 description 24
• WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 22
• 238000003556 assay Methods 0.000 description 22
• 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 22
• 150000001299 aldehydes Chemical class 0.000 description 21
• 125000006283 4-chlorobenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1Cl)C([H])([H])* 0.000 description 20
• PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Chemical compound BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 description 20
• 208000024891 symptom Diseases 0.000 description 20
• 208000014674 injury Diseases 0.000 description 19
• 238000002560 therapeutic procedure Methods 0.000 description 19
• 241001465754 Metazoa Species 0.000 description 18
• 239000012267 brine Substances 0.000 description 18
• 230000006378 damage Effects 0.000 description 18
• 239000003814 drug Substances 0.000 description 18
• BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 18
• 239000003921 oil Substances 0.000 description 18
• HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 18
• 238000003756 stirring Methods 0.000 description 18
• 238000009472 formulation Methods 0.000 description 17
• 235000019198 oils Nutrition 0.000 description 17
• 208000000094 Chronic Pain Diseases 0.000 description 16
• 239000012043 crude product Substances 0.000 description 16
• 150000002148 esters Chemical class 0.000 description 16
• 230000001965 increasing effect Effects 0.000 description 16
• 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 16
• QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 15
• 208000004454 Hyperalgesia Diseases 0.000 description 15
• 208000027418 Wounds and injury Diseases 0.000 description 15
• 229910001410 inorganic ion Inorganic materials 0.000 description 15
• CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 14
• KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 14
• 229940079593 drug Drugs 0.000 description 14
• 125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 description 14
• 238000000105 evaporative light scattering detection Methods 0.000 description 14
• 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 14
• 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 14
• 150000003233 pyrroles Chemical class 0.000 description 14
• 102000004868 N-Methyl-D-Aspartate Receptors Human genes 0.000 description 13
• 108090001041 N-Methyl-D-Aspartate Receptors Proteins 0.000 description 13
• 229910052777 Praseodymium Inorganic materials 0.000 description 13
• 210000004556 brain Anatomy 0.000 description 13
• 206010027175 memory impairment Diseases 0.000 description 13
• 229910000404 tripotassium phosphate Inorganic materials 0.000 description 13
• 235000019798 tripotassium phosphate Nutrition 0.000 description 13
• 239000008096 xylene Substances 0.000 description 13
• MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 12
• JRNVZBWKYDBUCA-UHFFFAOYSA-N N-chlorosuccinimide Chemical compound ClN1C(=O)CCC1=O JRNVZBWKYDBUCA-UHFFFAOYSA-N 0.000 description 12
• 208000005298 acute pain Diseases 0.000 description 12
• 125000004432 carbon atom Chemical group C* 0.000 description 12
• 239000000543 intermediate Substances 0.000 description 12
• 239000012044 organic layer Substances 0.000 description 12
• 238000012360 testing method Methods 0.000 description 12
• 150000003577 thiophenes Chemical class 0.000 description 12
• LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 12
• 206010012289 Dementia Diseases 0.000 description 11
• 238000004587 chromatography analysis Methods 0.000 description 11
• 230000006735 deficit Effects 0.000 description 11
• 238000003682 fluorination reaction Methods 0.000 description 11
• RLKHFSNWQCZBDC-UHFFFAOYSA-N n-(benzenesulfonyl)-n-fluorobenzenesulfonamide Chemical compound C=1C=CC=CC=1S(=O)(=O)N(F)S(=O)(=O)C1=CC=CC=C1 RLKHFSNWQCZBDC-UHFFFAOYSA-N 0.000 description 11
• 238000004007 reversed phase HPLC Methods 0.000 description 11
• 239000002904 solvent Substances 0.000 description 11
• 208000011580 syndromic disease Diseases 0.000 description 11
• MFGHPIAIHLKMBC-UHFFFAOYSA-N 4-[(4-chlorophenyl)methyl]thiophene-2-carbaldehyde Chemical compound C1=CC(Cl)=CC=C1CC1=CSC(C=O)=C1 MFGHPIAIHLKMBC-UHFFFAOYSA-N 0.000 description 10
• VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 10
• 208000035154 Hyperesthesia Diseases 0.000 description 10
• 206010015037 epilepsy Diseases 0.000 description 10
• 239000000463 material Substances 0.000 description 10
• 230000004044 response Effects 0.000 description 10
• 238000007363 ring formation reaction Methods 0.000 description 10
• OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 9
• 101100030361 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) pph-3 gene Proteins 0.000 description 9
• 239000004480 active ingredient Substances 0.000 description 9
• 239000002585 base Substances 0.000 description 9
• 230000008033 biological extinction Effects 0.000 description 9
• 239000000706 filtrate Substances 0.000 description 9
• 235000019253 formic acid Nutrition 0.000 description 9
• RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 9
• 229910052740 iodine Inorganic materials 0.000 description 9
• 239000007788 liquid Substances 0.000 description 9
• 239000010502 orange oil Substances 0.000 description 9
• 230000002093 peripheral effect Effects 0.000 description 9
• 230000008569 process Effects 0.000 description 9
• 150000003254 radicals Chemical class 0.000 description 9
• 238000007127 saponification reaction Methods 0.000 description 9
• 239000003826 tablet Substances 0.000 description 9
• 238000006478 transmetalation reaction Methods 0.000 description 9
• IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 8
• UGJMXCAKCUNAIE-UHFFFAOYSA-N Gabapentin Chemical compound OC(=O)CC1(CN)CCCCC1 UGJMXCAKCUNAIE-UHFFFAOYSA-N 0.000 description 8
• 235000019502 Orange oil Nutrition 0.000 description 8
• FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
• 206010053552 allodynia Diseases 0.000 description 8
• 230000027455 binding Effects 0.000 description 8
• 230000001684 chronic effect Effects 0.000 description 8
• 238000010511 deprotection reaction Methods 0.000 description 8
• 208000002173 dizziness Diseases 0.000 description 8
• 239000000284 extract Substances 0.000 description 8
• 230000006870 function Effects 0.000 description 8
• 230000005764 inhibitory process Effects 0.000 description 8
• 230000014759 maintenance of location Effects 0.000 description 8
• BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 8
• 239000012071 phase Substances 0.000 description 8
• 102000005962 receptors Human genes 0.000 description 8
• 108020003175 receptors Proteins 0.000 description 8
• 230000009467 reduction Effects 0.000 description 8
• 229920006395 saturated elastomer Polymers 0.000 description 8
• 239000012453 solvate Substances 0.000 description 8
• 239000000126 substance Substances 0.000 description 8
• 230000002194 synthesizing effect Effects 0.000 description 8
• FPGGTKZVZWFYPV-UHFFFAOYSA-M tetrabutylammonium fluoride Chemical compound [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 description 8
• 229930192474 thiophene Natural products 0.000 description 8
• NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 7
• 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 description 7
• 206010028980 Neoplasm Diseases 0.000 description 7
• 230000001154 acute effect Effects 0.000 description 7
• 125000002947 alkylene group Chemical group 0.000 description 7
• 208000010877 cognitive disease Diseases 0.000 description 7
• 238000009833 condensation Methods 0.000 description 7
• 230000005494 condensation Effects 0.000 description 7
• 230000004064 dysfunction Effects 0.000 description 7
• 239000011737 fluorine Substances 0.000 description 7
• 230000002085 persistent effect Effects 0.000 description 7
• 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 7
• 230000006977 prepulse inhibition Effects 0.000 description 7
• 239000000377 silicon dioxide Substances 0.000 description 7
• 239000000725 suspension Substances 0.000 description 7
• 238000004809 thin layer chromatography Methods 0.000 description 7
• 239000003981 vehicle Substances 0.000 description 7
• PCVIGYOOZPUNSI-UHFFFAOYSA-N 5-[(4-chlorophenyl)methyl]thiophene-2-carbaldehyde Chemical compound C1=CC(Cl)=CC=C1CC1=CC=C(C=O)S1 PCVIGYOOZPUNSI-UHFFFAOYSA-N 0.000 description 6
• 208000019901 Anxiety disease Diseases 0.000 description 6
• YCKRFDGAMUMZLT-UHFFFAOYSA-N Fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 description 6
• 241000282412 Homo Species 0.000 description 6
• 206010065390 Inflammatory pain Diseases 0.000 description 6
• WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 6
• BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 6
• 241000700159 Rattus Species 0.000 description 6
• YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
• 150000007513 acids Chemical class 0.000 description 6
• VSCWAEJMTAWNJL-UHFFFAOYSA-K aluminium trichloride Chemical compound Cl[Al](Cl)Cl VSCWAEJMTAWNJL-UHFFFAOYSA-K 0.000 description 6
• 230000003109 amnesic effect Effects 0.000 description 6
• 210000003169 central nervous system Anatomy 0.000 description 6
• 230000001143 conditioned effect Effects 0.000 description 6
• 230000003247 decreasing effect Effects 0.000 description 6
• UAOMVDZJSHZZME-UHFFFAOYSA-N diisopropylamine Chemical compound CC(C)NC(C)C UAOMVDZJSHZZME-UHFFFAOYSA-N 0.000 description 6
• 125000001153 fluoro group Chemical group F* 0.000 description 6
• HYBBIBNJHNGZAN-UHFFFAOYSA-N furfural Chemical compound O=CC1=CC=CO1 HYBBIBNJHNGZAN-UHFFFAOYSA-N 0.000 description 6
• 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 6
• 210000005036 nerve Anatomy 0.000 description 6
• 210000002569 neuron Anatomy 0.000 description 6
• 230000003647 oxidation Effects 0.000 description 6
• 238000007254 oxidation reaction Methods 0.000 description 6
• 208000033808 peripheral neuropathy Diseases 0.000 description 6
• 238000002953 preparative HPLC Methods 0.000 description 6
• 230000011514 reflex Effects 0.000 description 6
• KIWUVOGUEXMXSV-UHFFFAOYSA-N rhodanine Chemical compound O=C1CSC(=S)N1 KIWUVOGUEXMXSV-UHFFFAOYSA-N 0.000 description 6
• SQGYOTSLMSWVJD-UHFFFAOYSA-N silver(1+) nitrate Chemical compound [Ag+].[O-]N(=O)=O SQGYOTSLMSWVJD-UHFFFAOYSA-N 0.000 description 6
• 230000001225 therapeutic effect Effects 0.000 description 6
• GPWNWKWQOLEVEQ-UHFFFAOYSA-N 2,4-diaminopyrimidine-5-carbaldehyde Chemical compound NC1=NC=C(C=O)C(N)=N1 GPWNWKWQOLEVEQ-UHFFFAOYSA-N 0.000 description 5
• PPXUUPXQWDQNGO-UHFFFAOYSA-N 2-azidoacetic acid Chemical compound OC(=O)CN=[N+]=[N-] PPXUUPXQWDQNGO-UHFFFAOYSA-N 0.000 description 5
• QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 5
• 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 description 5
• 206010019196 Head injury Diseases 0.000 description 5
• HCUARRIEZVDMPT-UHFFFAOYSA-N Indole-2-carboxylic acid Chemical class C1=CC=C2NC(C(=O)O)=CC2=C1 HCUARRIEZVDMPT-UHFFFAOYSA-N 0.000 description 5
• ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 5
• 239000000556 agonist Substances 0.000 description 5
• 208000015802 attention deficit-hyperactivity disease Diseases 0.000 description 5
• 230000008901 benefit Effects 0.000 description 5
• 201000011510 cancer Diseases 0.000 description 5
• 239000000969 carrier Substances 0.000 description 5
• 210000001638 cerebellum Anatomy 0.000 description 5
• 239000003795 chemical substances by application Substances 0.000 description 5
• 238000004440 column chromatography Methods 0.000 description 5
• 230000003111 delayed effect Effects 0.000 description 5
• 125000004185 ester group Chemical group 0.000 description 5
• HVJJYOAPXBPQQV-UHFFFAOYSA-N ethyl 2-azidoacetate Chemical compound CCOC(=O)CN=[N+]=[N-] HVJJYOAPXBPQQV-UHFFFAOYSA-N 0.000 description 5
• 210000002683 foot Anatomy 0.000 description 5
• 125000004474 heteroalkylene group Chemical group 0.000 description 5
• 238000000338 in vitro Methods 0.000 description 5
• 238000001727 in vivo Methods 0.000 description 5
• 230000002757 inflammatory effect Effects 0.000 description 5
• 239000004615 ingredient Substances 0.000 description 5
• 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 5
• 239000010410 layer Substances 0.000 description 5
• DLEDOFVPSDKWEF-UHFFFAOYSA-N lithium butane Chemical compound [Li+].CCC[CH2-] DLEDOFVPSDKWEF-UHFFFAOYSA-N 0.000 description 5
• 210000000653 nervous system Anatomy 0.000 description 5
• 231100000189 neurotoxic Toxicity 0.000 description 5
• 230000002887 neurotoxic effect Effects 0.000 description 5
• 238000002360 preparation method Methods 0.000 description 5
• 230000035939 shock Effects 0.000 description 5
• 239000011780 sodium chloride Substances 0.000 description 5
• 208000020431 spinal cord injury Diseases 0.000 description 5
• 239000007858 starting material Substances 0.000 description 5
• 125000000547 substituted alkyl group Chemical group 0.000 description 5
• 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 5
• UBOXGVDOUJQMTN-UHFFFAOYSA-N 1,1,2-trichloroethane Chemical compound ClCC(Cl)Cl UBOXGVDOUJQMTN-UHFFFAOYSA-N 0.000 description 4
• SMNDYUVBFMFKNZ-UHFFFAOYSA-N 2-furoic acid Chemical compound OC(=O)C1=CC=CO1 SMNDYUVBFMFKNZ-UHFFFAOYSA-N 0.000 description 4
• 125000002941 2-furyl group Chemical group O1C([*])=C([H])C([H])=C1[H] 0.000 description 4
• 125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 description 4
• JOZWNDJXSGKSIE-UHFFFAOYSA-N 4-(2-phenylethyl)thiophene-2-carbaldehyde Chemical compound S1C(C=O)=CC(CCC=2C=CC=CC=2)=C1 JOZWNDJXSGKSIE-UHFFFAOYSA-N 0.000 description 4
• MRGBBKQOSUHKPF-UHFFFAOYSA-N 4-bromofuran-2-carbaldehyde Chemical compound BrC1=COC(C=O)=C1 MRGBBKQOSUHKPF-UHFFFAOYSA-N 0.000 description 4
• ZYSQCKYCBRQBHZ-UHFFFAOYSA-N 4-fluorofuran-2-carbaldehyde Chemical compound FC1=COC(C=O)=C1 ZYSQCKYCBRQBHZ-UHFFFAOYSA-N 0.000 description 4
• RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 4
• 208000031091 Amnestic disease Diseases 0.000 description 4
• XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 4
• ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 4
• 206010013886 Dysaesthesia Diseases 0.000 description 4
• 208000030814 Eating disease Diseases 0.000 description 4
• 102000004190 Enzymes Human genes 0.000 description 4
• 108090000790 Enzymes Proteins 0.000 description 4
• UEXCJVNBTNXOEH-UHFFFAOYSA-N Ethynylbenzene Chemical group C#CC1=CC=CC=C1 UEXCJVNBTNXOEH-UHFFFAOYSA-N 0.000 description 4
• 208000019454 Feeding and Eating disease Diseases 0.000 description 4
• DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
• 206010021143 Hypoxia Diseases 0.000 description 4
• OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 4
• 208000028017 Psychotic disease Diseases 0.000 description 4
• PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 4
• UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
• 208000007536 Thrombosis Diseases 0.000 description 4
• 230000006986 amnesia Effects 0.000 description 4
• 238000010171 animal model Methods 0.000 description 4
• 239000000164 antipsychotic agent Substances 0.000 description 4
• 230000036506 anxiety Effects 0.000 description 4
• 238000013459 approach Methods 0.000 description 4
• 239000007864 aqueous solution Substances 0.000 description 4
• WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 4
• 230000031709 bromination Effects 0.000 description 4
• 238000005893 bromination reaction Methods 0.000 description 4
• 239000000872 buffer Substances 0.000 description 4
• 208000015114 central nervous system disease Diseases 0.000 description 4
• 239000003153 chemical reaction reagent Substances 0.000 description 4
• 238000002512 chemotherapy Methods 0.000 description 4
• 238000005660 chlorination reaction Methods 0.000 description 4
• 125000004803 chlorobenzyl group Chemical group 0.000 description 4
• 230000001149 cognitive effect Effects 0.000 description 4
• 230000003920 cognitive function Effects 0.000 description 4
• 230000003750 conditioning effect Effects 0.000 description 4
• 230000007423 decrease Effects 0.000 description 4
• 206010012601 diabetes mellitus Diseases 0.000 description 4
• 238000003745 diagnosis Methods 0.000 description 4
• 235000014632 disordered eating Nutrition 0.000 description 4
• 229940088598 enzyme Drugs 0.000 description 4
• 230000001037 epileptic effect Effects 0.000 description 4
• 238000001914 filtration Methods 0.000 description 4
• 229960002870 gabapentin Drugs 0.000 description 4
• VKYKSIONXSXAKP-UHFFFAOYSA-N hexamethylenetetramine Chemical compound C1N(C2)CN3CN1CN2C3 VKYKSIONXSXAKP-UHFFFAOYSA-N 0.000 description 4
• 230000007062 hydrolysis Effects 0.000 description 4
• 238000006460 hydrolysis reaction Methods 0.000 description 4
• 230000006872 improvement Effects 0.000 description 4
• 208000035231 inattentive type attention deficit hyperactivity disease Diseases 0.000 description 4
• 230000004054 inflammatory process Effects 0.000 description 4
• INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 4
• ZCSHNCUQKCANBX-UHFFFAOYSA-N lithium diisopropylamide Chemical compound [Li+].CC(C)[N-]C(C)C ZCSHNCUQKCANBX-UHFFFAOYSA-N 0.000 description 4
• UBJFKNSINUCEAL-UHFFFAOYSA-N lithium;2-methylpropane Chemical compound [Li+].C[C-](C)C UBJFKNSINUCEAL-UHFFFAOYSA-N 0.000 description 4
• NUJOXMJBOLGQSY-UHFFFAOYSA-N manganese dioxide Chemical compound O=[Mn]=O NUJOXMJBOLGQSY-UHFFFAOYSA-N 0.000 description 4
• 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 description 4
• 150000004702 methyl esters Chemical class 0.000 description 4
• UAEPNZWRGJTJPN-UHFFFAOYSA-N methylcyclohexane Chemical compound CC1CCCCC1 UAEPNZWRGJTJPN-UHFFFAOYSA-N 0.000 description 4
• 229960005181 morphine Drugs 0.000 description 4
• DXASQZJWWGZNSF-UHFFFAOYSA-N n,n-dimethylmethanamine;sulfur trioxide Chemical group CN(C)C.O=S(=O)=O DXASQZJWWGZNSF-UHFFFAOYSA-N 0.000 description 4
• 201000001119 neuropathy Diseases 0.000 description 4
• 230000007823 neuropathy Effects 0.000 description 4
• 230000007935 neutral effect Effects 0.000 description 4
• 239000012074 organic phase Substances 0.000 description 4
• 208000035824 paresthesia Diseases 0.000 description 4
• 208000028173 post-traumatic stress disease Diseases 0.000 description 4
• 239000000843 powder Substances 0.000 description 4
• 239000002244 precipitate Substances 0.000 description 4
• 125000006239 protecting group Chemical group 0.000 description 4
• 208000020016 psychiatric disease Diseases 0.000 description 4
• 239000012363 selectfluor Substances 0.000 description 4
• QDRKDTQENPPHOJ-UHFFFAOYSA-N sodium ethoxide Chemical compound [Na+].CC[O-] QDRKDTQENPPHOJ-UHFFFAOYSA-N 0.000 description 4
• OVYTZAASVAZITK-UHFFFAOYSA-M sodium;ethanol;hydroxide Chemical compound [OH-].[Na+].CCO OVYTZAASVAZITK-UHFFFAOYSA-M 0.000 description 4
• 230000008733 trauma Effects 0.000 description 4
• MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 3
• 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 3
• PVOAHINGSUIXLS-UHFFFAOYSA-N 1-Methylpiperazine Chemical compound CN1CCNCC1 PVOAHINGSUIXLS-UHFFFAOYSA-N 0.000 description 3
• MREIFUWKYMNYTK-UHFFFAOYSA-N 1H-pyrrole Chemical class C=1C=CNC=1.C=1C=CNC=1 MREIFUWKYMNYTK-UHFFFAOYSA-N 0.000 description 3
• ZAMFMWOTDLEXLY-UHFFFAOYSA-N 1h-pyrrole;1,3-thiazole Chemical compound C=1C=CNC=1.C1=CSC=N1 ZAMFMWOTDLEXLY-UHFFFAOYSA-N 0.000 description 3
• OZAIFHULBGXAKX-UHFFFAOYSA-N 2-(2-cyanopropan-2-yldiazenyl)-2-methylpropanenitrile Chemical compound N#CC(C)(C)N=NC(C)(C)C#N OZAIFHULBGXAKX-UHFFFAOYSA-N 0.000 description 3
• SAYKNBQCVYQQJF-UHFFFAOYSA-N 4-(2-phenylethynyl)thiophene-2-carbaldehyde Chemical compound S1C(C=O)=CC(C#CC=2C=CC=CC=2)=C1 SAYKNBQCVYQQJF-UHFFFAOYSA-N 0.000 description 3
• HZXKGUWZFQJRBG-UHFFFAOYSA-N 4-(trifluoromethyl)furan-2-carbaldehyde Chemical compound FC(F)(F)C1=COC(C=O)=C1 HZXKGUWZFQJRBG-UHFFFAOYSA-N 0.000 description 3
• DBPMTQBXPQFOHN-VOTSOKGWSA-N 4-[(e)-2-phenylethenyl]furan-2-carbaldehyde Chemical compound O1C(C=O)=CC(\C=C\C=2C=CC=CC=2)=C1 DBPMTQBXPQFOHN-VOTSOKGWSA-N 0.000 description 3
• GZNONFRIPBEMRS-UHFFFAOYSA-N 4-cyclopropylfuran-2-carbaldehyde Chemical compound O1C(C=O)=CC(C2CC2)=C1 GZNONFRIPBEMRS-UHFFFAOYSA-N 0.000 description 3
• AAWOXRNFSSSREJ-UHFFFAOYSA-N 4-fluorothiophene-2-carbaldehyde Chemical compound FC1=CSC(C=O)=C1 AAWOXRNFSSSREJ-UHFFFAOYSA-N 0.000 description 3
• RNFIHRJWAKWIEM-UHFFFAOYSA-N 4-propan-2-ylfuran-2-carbaldehyde Chemical compound CC(C)C1=COC(C=O)=C1 RNFIHRJWAKWIEM-UHFFFAOYSA-N 0.000 description 3
• BEMMSXOPWRZIOY-UHFFFAOYSA-N 5-benzylfuran-2-carbaldehyde Chemical compound O1C(C=O)=CC=C1CC1=CC=CC=C1 BEMMSXOPWRZIOY-UHFFFAOYSA-N 0.000 description 3
• CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
• 206010003805 Autism Diseases 0.000 description 3
• 208000020706 Autistic disease Diseases 0.000 description 3
• 208000001387 Causalgia Diseases 0.000 description 3
• KZBUYRJDOAKODT-UHFFFAOYSA-N Chlorine Chemical compound ClCl KZBUYRJDOAKODT-UHFFFAOYSA-N 0.000 description 3
• 208000018652 Closed Head injury Diseases 0.000 description 3
• 208000028698 Cognitive impairment Diseases 0.000 description 3
• 208000013586 Complex regional pain syndrome type 1 Diseases 0.000 description 3
• 206010012239 Delusion Diseases 0.000 description 3
• 208000004547 Hallucinations Diseases 0.000 description 3
• 208000023105 Huntington disease Diseases 0.000 description 3
• DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
• 206010061218 Inflammation Diseases 0.000 description 3
• 108090000862 Ion Channels Proteins 0.000 description 3
• 102000004310 Ion Channels Human genes 0.000 description 3
• WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 3
• 241000124008 Mammalia Species 0.000 description 3
• KWYHDKDOAIKMQN-UHFFFAOYSA-N N,N,N',N'-tetramethylethylenediamine Chemical compound CN(C)CCN(C)C KWYHDKDOAIKMQN-UHFFFAOYSA-N 0.000 description 3
• 208000028389 Nerve injury Diseases 0.000 description 3
• 206010037779 Radiculopathy Diseases 0.000 description 3
• 201000001947 Reflex Sympathetic Dystrophy Diseases 0.000 description 3
• 108010006152 Serine racemase Proteins 0.000 description 3
• 102100035717 Serine racemase Human genes 0.000 description 3
• VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 3
• 238000006069 Suzuki reaction reaction Methods 0.000 description 3
• 208000030886 Traumatic Brain injury Diseases 0.000 description 3
• 150000001241 acetals Chemical class 0.000 description 3
• OQIQSTLJSLGHID-WNWIJWBNSA-N aflatoxin B1 Chemical compound C=1([C@@H]2C=CO[C@@H]2OC=1C=C(C1=2)OC)C=2OC(=O)C2=C1CCC2=O OQIQSTLJSLGHID-WNWIJWBNSA-N 0.000 description 3
• 150000001412 amines Chemical class 0.000 description 3
• 229940024606 amino acid Drugs 0.000 description 3
• 235000019270 ammonium chloride Nutrition 0.000 description 3
• 239000008346 aqueous phase Substances 0.000 description 3
• 230000006399 behavior Effects 0.000 description 3
• 230000003542 behavioural effect Effects 0.000 description 3
• 230000009286 beneficial effect Effects 0.000 description 3
• OBXSGRKNCOCTTM-UHFFFAOYSA-N benzyl diethyl phosphate Chemical compound CCOP(=O)(OCC)OCC1=CC=CC=C1 OBXSGRKNCOCTTM-UHFFFAOYSA-N 0.000 description 3
• 150000001642 boronic acid derivatives Chemical class 0.000 description 3
• 230000003925 brain function Effects 0.000 description 3
• GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Chemical compound BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 3
• 239000002775 capsule Substances 0.000 description 3
• 235000011089 carbon dioxide Nutrition 0.000 description 3
• 150000001733 carboxylic acid esters Chemical class 0.000 description 3
• 239000000544 cholinesterase inhibitor Substances 0.000 description 3
• KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
• 239000012230 colorless oil Substances 0.000 description 3
• 208000014439 complex regional pain syndrome type 2 Diseases 0.000 description 3
• 230000007547 defect Effects 0.000 description 3
• 231100000868 delusion Toxicity 0.000 description 3
• 239000003085 diluting agent Substances 0.000 description 3
• VDCSGNNYCFPWFK-UHFFFAOYSA-N diphenylsilane Chemical compound C=1C=CC=CC=1[SiH2]C1=CC=CC=C1 VDCSGNNYCFPWFK-UHFFFAOYSA-N 0.000 description 3
• 230000002708 enhancing effect Effects 0.000 description 3
• 125000004494 ethyl ester group Chemical group 0.000 description 3
• 210000003414 extremity Anatomy 0.000 description 3
• 150000002240 furans Chemical class 0.000 description 3
• 239000000499 gel Substances 0.000 description 3
• 238000007429 general method Methods 0.000 description 3
• 239000008187 granular material Substances 0.000 description 3
• 150000002390 heteroarenes Chemical class 0.000 description 3
• 210000001320 hippocampus Anatomy 0.000 description 3
• 239000001257 hydrogen Substances 0.000 description 3
• RCBVKBFIWMOMHF-UHFFFAOYSA-L hydroxy-(hydroxy(dioxo)chromio)oxy-dioxochromium;pyridine Chemical compound C1=CC=NC=C1.C1=CC=NC=C1.O[Cr](=O)(=O)O[Cr](O)(=O)=O RCBVKBFIWMOMHF-UHFFFAOYSA-L 0.000 description 3
• 230000001771 impaired effect Effects 0.000 description 3
• 150000002475 indoles Chemical class 0.000 description 3
• 230000026045 iodination Effects 0.000 description 3
• 238000006192 iodination reaction Methods 0.000 description 3
• 208000028867 ischemia Diseases 0.000 description 3
• 230000003902 lesion Effects 0.000 description 3
• 239000000314 lubricant Substances 0.000 description 3
• 230000007246 mechanism Effects 0.000 description 3
• 210000003205 muscle Anatomy 0.000 description 3
• 208000031225 myocardial ischemia Diseases 0.000 description 3
• 230000008764 nerve damage Effects 0.000 description 3
• 239000002664 nootropic agent Substances 0.000 description 3
• 230000001590 oxidative effect Effects 0.000 description 3
• 229910052763 palladium Inorganic materials 0.000 description 3
• 230000000750 progressive effect Effects 0.000 description 3
• 239000003368 psychostimulant agent Substances 0.000 description 3
• 238000001671 psychotherapy Methods 0.000 description 3
• 238000001953 recrystallisation Methods 0.000 description 3
• 230000002829 reductive effect Effects 0.000 description 3
• 230000000698 schizophrenic effect Effects 0.000 description 3
• 238000000926 separation method Methods 0.000 description 3
• 229910052710 silicon Inorganic materials 0.000 description 3
• 229910052708 sodium Inorganic materials 0.000 description 3
• 239000012279 sodium borohydride Substances 0.000 description 3
• 229910000033 sodium borohydride Inorganic materials 0.000 description 3
• 229910052938 sodium sulfate Inorganic materials 0.000 description 3
• 235000011152 sodium sulphate Nutrition 0.000 description 3
• 210000001032 spinal nerve Anatomy 0.000 description 3
• 229940124530 sulfonamide Drugs 0.000 description 3
• 150000003456 sulfonamides Chemical class 0.000 description 3
• 125000004434 sulfur atom Chemical group 0.000 description 3
• 238000013268 sustained release Methods 0.000 description 3
• 239000012730 sustained-release form Substances 0.000 description 3
• 201000008914 temporal lobe epilepsy Diseases 0.000 description 3
• 230000000472 traumatic effect Effects 0.000 description 3
• DTQVDTLACAAQTR-UHFFFAOYSA-N trifluoroacetic acid Substances OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 3
• 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 3
• 229920002554 vinyl polymer Polymers 0.000 description 3
• 208000009935 visceral pain Diseases 0.000 description 3
• SZRNBGXUGVUETL-UHFFFAOYSA-N (4-bromo-4,4-difluorobut-2-ynoxy)-tert-butyl-dimethylsilane Chemical compound CC(C)(C)[Si](C)(C)OCC#CC(F)(F)Br SZRNBGXUGVUETL-UHFFFAOYSA-N 0.000 description 2
• UVTUHTQNNGCVPI-UHFFFAOYSA-N (4-fluorofuran-2-yl)methanol Chemical compound OCC1=CC(F)=CO1 UVTUHTQNNGCVPI-UHFFFAOYSA-N 0.000 description 2
• UJQNOBISTKAIPR-UHFFFAOYSA-N (4-fluorothiophen-2-yl)methanol Chemical compound OCC1=CC(F)=CS1 UJQNOBISTKAIPR-UHFFFAOYSA-N 0.000 description 2
• ANQLQOQLYYSYQP-UHFFFAOYSA-N (5-fluorothiophen-2-yl)methanol Chemical compound OCC1=CC=C(F)S1 ANQLQOQLYYSYQP-UHFFFAOYSA-N 0.000 description 2
• SCYULBFZEHDVBN-UHFFFAOYSA-N 1,1-Dichloroethane Chemical compound CC(Cl)Cl SCYULBFZEHDVBN-UHFFFAOYSA-N 0.000 description 2
• RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 2
• RABBMOYULJIAFU-UHFFFAOYSA-N 1h-pyrrole;thiophene Chemical compound C=1C=CNC=1.C=1C=CSC=1 RABBMOYULJIAFU-UHFFFAOYSA-N 0.000 description 2
• FZFGCHRSCIKKOX-UHFFFAOYSA-N 2-(bromomethyl)-4-(trifluoromethyl)furan Chemical compound FC(F)(F)C1=COC(CBr)=C1 FZFGCHRSCIKKOX-UHFFFAOYSA-N 0.000 description 2
• 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 2
• LVKNKELFVHDHHN-UHFFFAOYSA-N 3-(2-phenylethyl)thiophene-2-carbaldehyde Chemical compound S1C=CC(CCC=2C=CC=CC=2)=C1C=O LVKNKELFVHDHHN-UHFFFAOYSA-N 0.000 description 2
• BCZHCWCOQDRYGS-UHFFFAOYSA-N 3-bromothiophene-2-carbaldehyde Chemical compound BrC=1C=CSC=1C=O BCZHCWCOQDRYGS-UHFFFAOYSA-N 0.000 description 2
• RBIGKSZIQCTIJF-UHFFFAOYSA-N 3-formylthiophene Chemical compound O=CC=1C=CSC=1 RBIGKSZIQCTIJF-UHFFFAOYSA-N 0.000 description 2
• 125000001541 3-thienyl group Chemical group S1C([H])=C([*])C([H])=C1[H] 0.000 description 2
• SUAKVCDYDUALQH-UHFFFAOYSA-N 4-(2-phenylethyl)furan-2-carbaldehyde Chemical compound O1C(C=O)=CC(CCC=2C=CC=CC=2)=C1 SUAKVCDYDUALQH-UHFFFAOYSA-N 0.000 description 2
• HHZQGWSGBIVHSL-UHFFFAOYSA-N 4-[(4-chlorophenyl)methyl]thiophene-3-carbaldehyde Chemical compound C1=CC(Cl)=CC=C1CC1=CSC=C1C=O HHZQGWSGBIVHSL-UHFFFAOYSA-N 0.000 description 2
• AXCTUMLEPJKRIX-IHWYPQMZSA-N 4-[(z)-prop-1-enyl]furan-2-carbaldehyde Chemical compound C\C=C/C1=COC(C=O)=C1 AXCTUMLEPJKRIX-IHWYPQMZSA-N 0.000 description 2
• HTEXKHXVQFVUDB-UHFFFAOYSA-N 4-[2-(4-chlorophenyl)ethyl]thiophene-3-carbaldehyde Chemical compound C1=CC(Cl)=CC=C1CCC1=CSC=C1C=O HTEXKHXVQFVUDB-UHFFFAOYSA-N 0.000 description 2
• KEXIUNXGSUAMNN-UHFFFAOYSA-N 4-benzylfuran-2-carbaldehyde Chemical compound O1C(C=O)=CC(CC=2C=CC=CC=2)=C1 KEXIUNXGSUAMNN-UHFFFAOYSA-N 0.000 description 2
• MOKRBDCJFCISEK-UHFFFAOYSA-N 4-benzylthiophene-3-carbaldehyde Chemical compound O=CC1=CSC=C1CC1=CC=CC=C1 MOKRBDCJFCISEK-UHFFFAOYSA-N 0.000 description 2
• ZDVHJQOCVBTMOF-UHFFFAOYSA-N 4-bromothiophene-3-carbaldehyde Chemical compound BrC1=CSC=C1C=O ZDVHJQOCVBTMOF-UHFFFAOYSA-N 0.000 description 2
• 125000000242 4-chlorobenzoyl group Chemical group ClC1=CC=C(C(=O)*)C=C1 0.000 description 2
• PPVKGKYHKXSMLK-UHFFFAOYSA-N 4-ethenylfuran-2-carbaldehyde Chemical compound C=CC1=COC(C=O)=C1 PPVKGKYHKXSMLK-UHFFFAOYSA-N 0.000 description 2
• BLHZUMDWLLFLJC-UHFFFAOYSA-N 4-methylfuran-2-carbaldehyde Chemical compound CC1=COC(C=O)=C1 BLHZUMDWLLFLJC-UHFFFAOYSA-N 0.000 description 2
• IBWSJGDUGPZUJV-UHFFFAOYSA-N 4-phenylthiophene-3-carbaldehyde Chemical compound O=CC1=CSC=C1C1=CC=CC=C1 IBWSJGDUGPZUJV-UHFFFAOYSA-N 0.000 description 2
• VOROEQBFPPIACJ-UHFFFAOYSA-N 5-Phosphononorvaline Chemical compound OC(=O)C(N)CCCP(O)(O)=O VOROEQBFPPIACJ-UHFFFAOYSA-N 0.000 description 2
• KURANAVGCJMDFR-UHFFFAOYSA-N 5-fluorothiophene-2-carbaldehyde Chemical compound FC1=CC=C(C=O)S1 KURANAVGCJMDFR-UHFFFAOYSA-N 0.000 description 2
• CDBAAGJKGCQYLA-UHFFFAOYSA-N 5-fluorothiophene-3-carbaldehyde Chemical compound FC1=CC(C=O)=CS1 CDBAAGJKGCQYLA-UHFFFAOYSA-N 0.000 description 2
• ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 2
• 208000006888 Agnosia Diseases 0.000 description 2
• 241001047040 Agnosia Species 0.000 description 2
• QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 2
• 206010002660 Anoxia Diseases 0.000 description 2
• 241000976983 Anoxia Species 0.000 description 2
• 206010003062 Apraxia Diseases 0.000 description 2
• 208000020925 Bipolar disease Diseases 0.000 description 2
• 208000014644 Brain disease Diseases 0.000 description 2
• KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 2
• 208000017667 Chronic Disease Diseases 0.000 description 2
• 206010011968 Decreased immune responsiveness Diseases 0.000 description 2
• YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 2
• 102000004980 Dopamine D2 Receptors Human genes 0.000 description 2
• 108090001111 Dopamine D2 Receptors Proteins 0.000 description 2
• 201000010374 Down Syndrome Diseases 0.000 description 2
• 208000032274 Encephalopathy Diseases 0.000 description 2
• PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 2
• 208000027776 Extrapyramidal disease Diseases 0.000 description 2
• PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
• 239000004471 Glycine Substances 0.000 description 2
• 208000010496 Heart Arrest Diseases 0.000 description 2
• 241000701085 Human alphaherpesvirus 3 Species 0.000 description 2
• UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
• YZCKVEUIGOORGS-UHFFFAOYSA-N Hydrogen atom Chemical class [H] YZCKVEUIGOORGS-UHFFFAOYSA-N 0.000 description 2
• MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
• 208000020358 Learning disease Diseases 0.000 description 2
• 240000007472 Leucaena leucocephala Species 0.000 description 2
• 235000010643 Leucaena leucocephala Nutrition 0.000 description 2
• BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
• 208000019022 Mood disease Diseases 0.000 description 2
• 238000012347 Morris Water Maze Methods 0.000 description 2
• 208000005314 Multi-Infarct Dementia Diseases 0.000 description 2
• 208000000112 Myalgia Diseases 0.000 description 2
• 206010028570 Myelopathy Diseases 0.000 description 2
• 206010028923 Neonatal asphyxia Diseases 0.000 description 2
• 208000037212 Neonatal hypoxic and ischemic brain injury Diseases 0.000 description 2
• 208000009668 Neurobehavioral Manifestations Diseases 0.000 description 2
• 208000001294 Nociceptive Pain Diseases 0.000 description 2
• 208000008589 Obesity Diseases 0.000 description 2
• 229910019142 PO4 Inorganic materials 0.000 description 2
• 206010033425 Pain in extremity Diseases 0.000 description 2
• 208000003251 Pruritus Diseases 0.000 description 2
• SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 2
• 206010040030 Sensory loss Diseases 0.000 description 2
• 206010041250 Social phobia Diseases 0.000 description 2
• WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 2
• CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
• 229930006000 Sucrose Natural products 0.000 description 2
• YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 2
• XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
• 201000004810 Vascular dementia Diseases 0.000 description 2
• 208000036142 Viral infection Diseases 0.000 description 2
• VKIJXFIYBAYHOE-VOTSOKGWSA-N [(e)-2-phenylethenyl]boronic acid Chemical compound OB(O)\C=C\C1=CC=CC=C1 VKIJXFIYBAYHOE-VOTSOKGWSA-N 0.000 description 2
• PNDPGZBMCMUPRI-XXSWNUTMSA-N [125I][125I] Chemical compound [125I][125I] PNDPGZBMCMUPRI-XXSWNUTMSA-N 0.000 description 2
• 230000002159 abnormal effect Effects 0.000 description 2
• DHKHKXVYLBGOIT-UHFFFAOYSA-N acetaldehyde Diethyl Acetal Natural products CCOC(C)OCC DHKHKXVYLBGOIT-UHFFFAOYSA-N 0.000 description 2
• 229960000583 acetic acid Drugs 0.000 description 2
• 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 2
• 230000002378 acidificating effect Effects 0.000 description 2
• 239000002671 adjuvant Substances 0.000 description 2
• 230000002411 adverse Effects 0.000 description 2
• 230000032683 aging Effects 0.000 description 2
• 230000003281 allosteric effect Effects 0.000 description 2
• 150000001408 amides Chemical class 0.000 description 2
• 150000001413 amino acids Chemical class 0.000 description 2
• 229910021529 ammonia Inorganic materials 0.000 description 2
• 238000004458 analytical method Methods 0.000 description 2
• 230000007953 anoxia Effects 0.000 description 2
• 230000000561 anti-psychotic effect Effects 0.000 description 2
• 239000000935 antidepressant agent Substances 0.000 description 2
• 229940005513 antidepressants Drugs 0.000 description 2
• 229940054051 antipsychotic indole derivative Drugs 0.000 description 2
• 229940005529 antipsychotics Drugs 0.000 description 2
• 201000007201 aphasia Diseases 0.000 description 2
• 229910052786 argon Inorganic materials 0.000 description 2
• 238000002820 assay format Methods 0.000 description 2
• 239000012298 atmosphere Substances 0.000 description 2
• WGQKYBSKWIADBV-UHFFFAOYSA-N benzylamine Chemical compound NCC1=CC=CC=C1 WGQKYBSKWIADBV-UHFFFAOYSA-N 0.000 description 2
• 239000011230 binding agent Substances 0.000 description 2
• 229910052796 boron Inorganic materials 0.000 description 2
• ZADPBFCGQRWHPN-UHFFFAOYSA-N boronic acid Chemical compound OBO ZADPBFCGQRWHPN-UHFFFAOYSA-N 0.000 description 2
• FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 2
• YKPUWZUDDOIDPM-SOFGYWHQSA-N capsaicin Chemical compound COC1=CC(CNC(=O)CCCC\C=C\C(C)C)=CC=C1O YKPUWZUDDOIDPM-SOFGYWHQSA-N 0.000 description 2
• 229910002091 carbon monoxide Inorganic materials 0.000 description 2
• 239000000679 carrageenan Substances 0.000 description 2
• 235000010418 carrageenan Nutrition 0.000 description 2
• 229920001525 carrageenan Polymers 0.000 description 2
• 229940113118 carrageenan Drugs 0.000 description 2
• 230000008859 change Effects 0.000 description 2
• IJOOHPMOJXWVHK-UHFFFAOYSA-N chlorotrimethylsilane Chemical compound C[Si](C)(C)Cl IJOOHPMOJXWVHK-UHFFFAOYSA-N 0.000 description 2
• 230000007278 cognition impairment Effects 0.000 description 2
• 230000037411 cognitive enhancing Effects 0.000 description 2
• 230000006835 compression Effects 0.000 description 2
• 238000007906 compression Methods 0.000 description 2
• 230000006866 deterioration Effects 0.000 description 2
• 229910052805 deuterium Inorganic materials 0.000 description 2
• AZSZCFSOHXEJQE-UHFFFAOYSA-N dibromodifluoromethane Chemical compound FC(F)(Br)Br AZSZCFSOHXEJQE-UHFFFAOYSA-N 0.000 description 2
• 229940043279 diisopropylamine Drugs 0.000 description 2
• QLTXKCWMEZIHBJ-PJGJYSAQSA-N dizocilpine maleate Chemical compound OC(=O)\C=C/C(O)=O.C12=CC=CC=C2[C@]2(C)C3=CC=CC=C3C[C@H]1N2 QLTXKCWMEZIHBJ-PJGJYSAQSA-N 0.000 description 2
• ADEBPBSSDYVVLD-UHFFFAOYSA-N donepezil Chemical compound O=C1C=2C=C(OC)C(OC)=CC=2CC1CC(CC1)CCN1CC1=CC=CC=C1 ADEBPBSSDYVVLD-UHFFFAOYSA-N 0.000 description 2
• 238000010828 elution Methods 0.000 description 2
• 239000002532 enzyme inhibitor Substances 0.000 description 2
• 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 2
• BVEQPQVAYIFRCK-UHFFFAOYSA-N ethyl 2-azido-3-(4-fluorothiophen-2-yl)prop-2-enoate Chemical compound CCOC(=O)C(N=[N+]=[N-])=CC1=CC(F)=CS1 BVEQPQVAYIFRCK-UHFFFAOYSA-N 0.000 description 2
• GMHVTKGBAZYUHW-UHFFFAOYSA-N ethyl 2-azido-3-(5-fluorofuran-2-yl)prop-2-enoate Chemical compound CCOC(=O)C(N=[N+]=[N-])=CC1=CC=C(F)O1 GMHVTKGBAZYUHW-UHFFFAOYSA-N 0.000 description 2
• CEOZSWLHUWRAHZ-UHFFFAOYSA-N ethyl 2-azido-3-[4-(2-phenylethyl)furan-2-yl]prop-2-enoate Chemical compound O1C(C=C(C(=O)OCC)N=[N+]=[N-])=CC(CCC=2C=CC=CC=2)=C1 CEOZSWLHUWRAHZ-UHFFFAOYSA-N 0.000 description 2
• LVFGFBHCDFCWEN-UHFFFAOYSA-N ethyl 2-azidoprop-2-enoate Chemical compound CCOC(=O)C(=C)N=[N+]=[N-] LVFGFBHCDFCWEN-UHFFFAOYSA-N 0.000 description 2
• 238000001704 evaporation Methods 0.000 description 2
• 230000008020 evaporation Effects 0.000 description 2
• 230000002964 excitative effect Effects 0.000 description 2
• 230000008434 fear extinction Effects 0.000 description 2
• 230000006390 fear memory Effects 0.000 description 2
• CNUDBTRUORMMPA-UHFFFAOYSA-N formylthiophene Chemical class O=CC1=CC=CS1 CNUDBTRUORMMPA-UHFFFAOYSA-N 0.000 description 2
• LTVDTKRMOQDRCH-UHFFFAOYSA-N furan;1h-pyrrole Chemical compound C=1C=CNC=1.C=1C=COC=1 LTVDTKRMOQDRCH-UHFFFAOYSA-N 0.000 description 2
• 229930195712 glutamate Natural products 0.000 description 2
• 125000001188 haloalkyl group Chemical group 0.000 description 2
• 230000026030 halogenation Effects 0.000 description 2
• 238000005658 halogenation reaction Methods 0.000 description 2
• 230000035876 healing Effects 0.000 description 2
• 239000004312 hexamethylene tetramine Substances 0.000 description 2
• 235000010299 hexamethylene tetramine Nutrition 0.000 description 2
• 150000002431 hydrogen Chemical class 0.000 description 2
• 125000004356 hydroxy functional group Chemical group O* 0.000 description 2
• 208000013403 hyperactivity Diseases 0.000 description 2
• 230000007954 hypoxia Effects 0.000 description 2
• 239000012442 inert solvent Substances 0.000 description 2
• 238000002347 injection Methods 0.000 description 2
• 239000007924 injection Substances 0.000 description 2
• 238000001990 intravenous administration Methods 0.000 description 2
• 238000002955 isolation Methods 0.000 description 2
• KFZMGEQAYNKOFK-UHFFFAOYSA-N isopropyl alcohol Natural products CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
• 230000007803 itching Effects 0.000 description 2
• 230000008449 language Effects 0.000 description 2
• 201000003723 learning disability Diseases 0.000 description 2
• 239000003446 ligand Substances 0.000 description 2
• KWGKDLIKAYFUFQ-UHFFFAOYSA-M lithium chloride Chemical compound [Li+].[Cl-] KWGKDLIKAYFUFQ-UHFFFAOYSA-M 0.000 description 2
• 238000003760 magnetic stirring Methods 0.000 description 2
• 230000001404 mediated effect Effects 0.000 description 2
• 230000009245 menopause Effects 0.000 description 2
• 229960004011 methenamine Drugs 0.000 description 2
• GYNNXHKOJHMOHS-UHFFFAOYSA-N methyl-cycloheptane Natural products CC1CCCCCC1 GYNNXHKOJHMOHS-UHFFFAOYSA-N 0.000 description 2
• 239000003607 modifier Substances 0.000 description 2
• 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 description 2
• 238000000465 moulding Methods 0.000 description 2
• 201000006417 multiple sclerosis Diseases 0.000 description 2
• 230000000926 neurological effect Effects 0.000 description 2
• 230000003955 neuronal function Effects 0.000 description 2
• QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 2
• 230000003040 nociceptive effect Effects 0.000 description 2
• 231100000252 nontoxic Toxicity 0.000 description 2
• 230000003000 nontoxic effect Effects 0.000 description 2
• 230000001473 noxious effect Effects 0.000 description 2
• 231100000862 numbness Toxicity 0.000 description 2
• 235000020824 obesity Nutrition 0.000 description 2
• 229940005483 opioid analgesics Drugs 0.000 description 2
• 125000004430 oxygen atom Chemical group O* 0.000 description 2
• 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 description 2
• ZRSNZINYAWTAHE-UHFFFAOYSA-N p-methoxybenzaldehyde Chemical compound COC1=CC=C(C=O)C=C1 ZRSNZINYAWTAHE-UHFFFAOYSA-N 0.000 description 2
• 208000019906 panic disease Diseases 0.000 description 2
• 238000007911 parenteral administration Methods 0.000 description 2
• 230000007310 pathophysiology Effects 0.000 description 2
• 230000008447 perception Effects 0.000 description 2
• 208000033300 perinatal asphyxia Diseases 0.000 description 2
• 239000003208 petroleum Substances 0.000 description 2
• 208000019899 phobic disease Diseases 0.000 description 2
• NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
• 239000010452 phosphate Substances 0.000 description 2
• 230000006461 physiological response Effects 0.000 description 2
• 239000000902 placebo Substances 0.000 description 2
• 229940068196 placebo Drugs 0.000 description 2
• 229920001223 polyethylene glycol Polymers 0.000 description 2
• 230000000069 prophylactic effect Effects 0.000 description 2
• 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
• LEHBURLTIWGHEM-UHFFFAOYSA-N pyridinium chlorochromate Chemical compound [O-][Cr](Cl)(=O)=O.C1=CC=[NH+]C=C1 LEHBURLTIWGHEM-UHFFFAOYSA-N 0.000 description 2
• ZSKGQVFRTSEPJT-UHFFFAOYSA-N pyrrole-2-carboxaldehyde Chemical compound O=CC1=CC=CN1 ZSKGQVFRTSEPJT-UHFFFAOYSA-N 0.000 description 2
• 230000002285 radioactive effect Effects 0.000 description 2
• 230000001105 regulatory effect Effects 0.000 description 2
• 238000012552 review Methods 0.000 description 2
• 230000035945 sensitivity Effects 0.000 description 2
• 229960001153 serine Drugs 0.000 description 2
• QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 2
• 208000019116 sleep disease Diseases 0.000 description 2
• 235000017557 sodium bicarbonate Nutrition 0.000 description 2
• 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
• 239000008247 solid mixture Substances 0.000 description 2
• 241000894007 species Species 0.000 description 2
• 230000002269 spontaneous effect Effects 0.000 description 2
• 239000010902 straw Substances 0.000 description 2
• 208000011117 substance-related disease Diseases 0.000 description 2
• 125000005346 substituted cycloalkyl group Chemical group 0.000 description 2
• 239000005720 sucrose Substances 0.000 description 2
• 150000003457 sulfones Chemical class 0.000 description 2
• 230000002459 sustained effect Effects 0.000 description 2
• YLJREFDVOIBQDA-UHFFFAOYSA-N tacrine Chemical compound C1=CC=C2C(N)=C(CCCC3)C3=NC2=C1 YLJREFDVOIBQDA-UHFFFAOYSA-N 0.000 description 2
• HZTCVVJJSBKXMA-UHFFFAOYSA-N tert-butyl-[(3,3-difluoro-2h-furan-5-yl)methoxy]-dimethylsilane Chemical compound CC(C)(C)[Si](C)(C)OCC1=CC(F)(F)CO1 HZTCVVJJSBKXMA-UHFFFAOYSA-N 0.000 description 2
• VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 2
• 101150054171 thf1 gene Proteins 0.000 description 2
• 150000003557 thiazoles Chemical group 0.000 description 2
• 125000005309 thioalkoxy group Chemical group 0.000 description 2
• WEMNATFLVGEPEW-UHFFFAOYSA-N thiophene Chemical compound C=1C=CSC=1.C=1C=CSC=1 WEMNATFLVGEPEW-UHFFFAOYSA-N 0.000 description 2
• 210000001519 tissue Anatomy 0.000 description 2
• 230000000451 tissue damage Effects 0.000 description 2
• 231100000827 tissue damage Toxicity 0.000 description 2
• 230000000699 topical effect Effects 0.000 description 2
• 231100000331 toxic Toxicity 0.000 description 2
• 230000002588 toxic effect Effects 0.000 description 2
• WLPUWLXVBWGYMZ-UHFFFAOYSA-N tricyclohexylphosphine Chemical compound C1CCCCC1P(C1CCCCC1)C1CCCCC1 WLPUWLXVBWGYMZ-UHFFFAOYSA-N 0.000 description 2
• PYOKUURKVVELLB-UHFFFAOYSA-N trimethyl orthoformate Chemical compound COC(OC)OC PYOKUURKVVELLB-UHFFFAOYSA-N 0.000 description 2
• ONDSBJMLAHVLMI-UHFFFAOYSA-N trimethylsilyldiazomethane Chemical compound C[Si](C)(C)[CH-][N+]#N ONDSBJMLAHVLMI-UHFFFAOYSA-N 0.000 description 2
• 208000001072 type 2 diabetes mellitus Diseases 0.000 description 2
• 125000004417 unsaturated alkyl group Chemical group 0.000 description 2
• 230000009385 viral infection Effects 0.000 description 2
• 230000003313 weakening effect Effects 0.000 description 2
• 230000003936 working memory Effects 0.000 description 2
• UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 2
• QCHFTSOMWOSFHM-WPRPVWTQSA-N (+)-Pilocarpine Chemical compound C1OC(=O)[C@@H](CC)[C@H]1CC1=CN=CN1C QCHFTSOMWOSFHM-WPRPVWTQSA-N 0.000 description 1
• ITOFPJRDSCGOSA-KZLRUDJFSA-N (2s)-2-[[(4r)-4-[(3r,5r,8r,9s,10s,13r,14s,17r)-3-hydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]pentanoyl]amino]-3-(1h-indol-3-yl)propanoic acid Chemical class C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H](CC[C@]13C)[C@@H]2[C@@H]3CC[C@@H]1[C@H](C)CCC(=O)N[C@H](C(O)=O)CC1=CNC2=CC=CC=C12 ITOFPJRDSCGOSA-KZLRUDJFSA-N 0.000 description 1
• PXZNJHHUYJRFPZ-UHFFFAOYSA-N (4-bromothiophen-2-yl)methanol Chemical compound OCC1=CC(Br)=CS1 PXZNJHHUYJRFPZ-UHFFFAOYSA-N 0.000 description 1
• ABNTYKOJPTVOSK-UHFFFAOYSA-N (4-bromothiophen-2-yl)methoxy-tert-butyl-diphenylsilane Chemical compound C=1C=CC=CC=1[Si](C=1C=CC=CC=1)(C(C)(C)C)OCC1=CC(Br)=CS1 ABNTYKOJPTVOSK-UHFFFAOYSA-N 0.000 description 1
• OAYWHBIVRKFUJQ-UHFFFAOYSA-N (4-chlorophenyl)methyl diethyl phosphate Chemical compound CCOP(=O)(OCC)OCC1=CC=C(Cl)C=C1 OAYWHBIVRKFUJQ-UHFFFAOYSA-N 0.000 description 1
• LVLCWVAVXNPOFF-UHFFFAOYSA-N (4-formylthiophen-3-yl)boronic acid Chemical compound OB(O)C1=CSC=C1C=O LVLCWVAVXNPOFF-UHFFFAOYSA-N 0.000 description 1
• JUWYQISLQJRRNT-UHFFFAOYSA-N (5-formylfuran-2-yl)boronic acid Chemical compound OB(O)C1=CC=C(C=O)O1 JUWYQISLQJRRNT-UHFFFAOYSA-N 0.000 description 1
• DEQOVKFWRPOPQP-UHFFFAOYSA-N (5-formylthiophen-2-yl)boronic acid Chemical compound OB(O)C1=CC=C(C=O)S1 DEQOVKFWRPOPQP-UHFFFAOYSA-N 0.000 description 1
• ZCUFJAORCNFWOF-UHFFFAOYSA-N (5-formylthiophen-3-yl)boronic acid Chemical compound OB(O)C1=CSC(C=O)=C1 ZCUFJAORCNFWOF-UHFFFAOYSA-N 0.000 description 1
• 125000006732 (C1-C15) alkyl group Chemical group 0.000 description 1
• KWTSXDURSIMDCE-QMMMGPOBSA-N (S)-amphetamine Chemical compound C[C@H](N)CC1=CC=CC=C1 KWTSXDURSIMDCE-QMMMGPOBSA-N 0.000 description 1
• PYHRZPFZZDCOPH-QXGOIDDHSA-N (S)-amphetamine sulfate Chemical compound [H+].[H+].[O-]S([O-])(=O)=O.C[C@H](N)CC1=CC=CC=C1.C[C@H](N)CC1=CC=CC=C1 PYHRZPFZZDCOPH-QXGOIDDHSA-N 0.000 description 1
• 125000000196 1,4-pentadienyl group Chemical group [H]C([*])=C([H])C([H])([H])C([H])=C([H])[H] 0.000 description 1
• MDAOZTFXAXKOTE-UHFFFAOYSA-N 1,5-dihydropyrrolo[3,4-b]pyrrole Chemical class N1C=C2NC=CC2=C1 MDAOZTFXAXKOTE-UHFFFAOYSA-N 0.000 description 1
• BVQPVBZRJSFOEZ-UHFFFAOYSA-N 1-chloro-4-(diethoxyphosphorylmethyl)benzene Chemical compound CCOP(=O)(OCC)CC1=CC=C(Cl)C=C1 BVQPVBZRJSFOEZ-UHFFFAOYSA-N 0.000 description 1
• FCBJLBCGHCTPAQ-UHFFFAOYSA-N 1-fluorobutane Chemical compound CCCCF FCBJLBCGHCTPAQ-UHFFFAOYSA-N 0.000 description 1
• 125000001637 1-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C(*)=C([H])C([H])=C([H])C2=C1[H] 0.000 description 1
• 125000001462 1-pyrrolyl group Chemical group [*]N1C([H])=C([H])C([H])=C1[H] 0.000 description 1
• 125000004206 2,2,2-trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 description 1
• TZFQLTFUDURGJK-UHFFFAOYSA-N 2-(2-phenylethyl)thiophene-3-carbaldehyde Chemical compound C1=CSC(CCC=2C=CC=CC=2)=C1C=O TZFQLTFUDURGJK-UHFFFAOYSA-N 0.000 description 1
• HWSDRAPTZRYXHN-UHFFFAOYSA-N 2-(4-chlorophenyl)ethenylboronic acid Chemical compound OB(O)C=CC1=CC=C(Cl)C=C1 HWSDRAPTZRYXHN-UHFFFAOYSA-N 0.000 description 1
• BPXKZEMBEZGUAH-UHFFFAOYSA-N 2-(chloromethoxy)ethyl-trimethylsilane Chemical compound C[Si](C)(C)CCOCCl BPXKZEMBEZGUAH-UHFFFAOYSA-N 0.000 description 1
• 125000004174 2-benzimidazolyl group Chemical group [H]N1C(*)=NC2=C([H])C([H])=C([H])C([H])=C12 0.000 description 1
• VJLPVNPJLPNWFJ-UHFFFAOYSA-N 2-benzyloxolane-2-carboxylic acid Chemical compound C=1C=CC=CC=1CC1(C(=O)O)CCCO1 VJLPVNPJLPNWFJ-UHFFFAOYSA-N 0.000 description 1
• IQHSSYROJYPFDV-UHFFFAOYSA-N 2-bromo-1,3-dichloro-5-(trifluoromethyl)benzene Chemical group FC(F)(F)C1=CC(Cl)=C(Br)C(Cl)=C1 IQHSSYROJYPFDV-UHFFFAOYSA-N 0.000 description 1
• JYUOZYKKKGDMKH-UHFFFAOYSA-N 2-methyl-4-(trifluoromethyl)furan Chemical compound CC1=CC(C(F)(F)F)=CO1 JYUOZYKKKGDMKH-UHFFFAOYSA-N 0.000 description 1
• 125000001622 2-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C(*)C([H])=C([H])C2=C1[H] 0.000 description 1
• RLQZIECDMISZHS-UHFFFAOYSA-N 2-phenylcyclohexa-2,5-diene-1,4-dione Chemical compound O=C1C=CC(=O)C(C=2C=CC=CC=2)=C1 RLQZIECDMISZHS-UHFFFAOYSA-N 0.000 description 1
• 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
• 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 description 1
• 125000000389 2-pyrrolyl group Chemical group [H]N1C([*])=C([H])C([H])=C1[H] 0.000 description 1
• AZTHCNQWFYIVRO-UHFFFAOYSA-N 3-(2-phenylethynyl)furan-2-carbaldehyde Chemical compound O1C=CC(C#CC=2C=CC=CC=2)=C1C=O AZTHCNQWFYIVRO-UHFFFAOYSA-N 0.000 description 1
• PQASUMRZUQCTOP-UHFFFAOYSA-N 3-(2-phenylethynyl)thiophene-2-carbaldehyde Chemical compound S1C=CC(C#CC=2C=CC=CC=2)=C1C=O PQASUMRZUQCTOP-UHFFFAOYSA-N 0.000 description 1
• VCNMJFXOIMIGNG-UHFFFAOYSA-N 3-[(4-chlorophenyl)methyl]thiophene Chemical compound C1=CC(Cl)=CC=C1CC1=CSC=C1 VCNMJFXOIMIGNG-UHFFFAOYSA-N 0.000 description 1
• 125000000474 3-butynyl group Chemical group [H]C#CC([H])([H])C([H])([H])* 0.000 description 1
• 125000003682 3-furyl group Chemical group O1C([H])=C([*])C([H])=C1[H] 0.000 description 1
• 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 description 1
• 125000001397 3-pyrrolyl group Chemical group [H]N1C([H])=C([*])C([H])=C1[H] 0.000 description 1
• XBXZTENDDALBBV-UHFFFAOYSA-N 4,4-difluoropent-2-yne-1,5-diol Chemical compound OCC#CC(F)(F)CO XBXZTENDDALBBV-UHFFFAOYSA-N 0.000 description 1
• TUFORXFWYVAOOP-UHFFFAOYSA-N 4-(2-phenylethynyl)furan-2-carbaldehyde Chemical compound O1C(C=O)=CC(C#CC=2C=CC=CC=2)=C1 TUFORXFWYVAOOP-UHFFFAOYSA-N 0.000 description 1
• VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 1
• ZXSVWILBEKFPJA-UHFFFAOYSA-N 4-[2-(4-chlorophenyl)ethenyl]thiophene-3-carbaldehyde Chemical compound C1=CC(Cl)=CC=C1C=CC1=CSC=C1C=O ZXSVWILBEKFPJA-UHFFFAOYSA-N 0.000 description 1
• QEWYMYPSEOCHQV-UHFFFAOYSA-N 4-bromo-3h-thiophen-2-one Chemical compound BrC1=CSC(=O)C1 QEWYMYPSEOCHQV-UHFFFAOYSA-N 0.000 description 1
• OONJRWDQJMBPMF-UHFFFAOYSA-N 4-bromo-6h-thieno[2,3-b]pyrrole-5-carboxylic acid Chemical compound S1C=CC2=C1NC(C(=O)O)=C2Br OONJRWDQJMBPMF-UHFFFAOYSA-N 0.000 description 1
• RKIDDEGICSMIJA-UHFFFAOYSA-N 4-chlorobenzoyl chloride Chemical compound ClC(=O)C1=CC=C(Cl)C=C1 RKIDDEGICSMIJA-UHFFFAOYSA-N 0.000 description 1
• 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 1
• KDDQRKBRJSGMQE-UHFFFAOYSA-N 4-thiazolyl Chemical group [C]1=CSC=N1 KDDQRKBRJSGMQE-UHFFFAOYSA-N 0.000 description 1
• PLJIVNLEQUBQTH-UHFFFAOYSA-N 4h-furo[3,2-b]pyrrole Chemical class O1C=CC2=C1C=CN2 PLJIVNLEQUBQTH-UHFFFAOYSA-N 0.000 description 1
• HBZGBHPZCXAXIA-UHFFFAOYSA-N 5-(2-azido-3-ethoxy-3-oxoprop-1-enyl)furan-2-carboxylic acid Chemical compound CCOC(=O)C(N=[N+]=[N-])=CC1=CC=C(C(O)=O)O1 HBZGBHPZCXAXIA-UHFFFAOYSA-N 0.000 description 1
• CBMDSKURMHSKDR-UHFFFAOYSA-N 5-(2-phenylethyl)thiophene-2-carbaldehyde Chemical compound S1C(C=O)=CC=C1CCC1=CC=CC=C1 CBMDSKURMHSKDR-UHFFFAOYSA-N 0.000 description 1
• DFUTWTAXOYDQRR-UHFFFAOYSA-N 5-(2-phenylethyl)thiophene-3-carbaldehyde Chemical compound O=CC1=CSC(CCC=2C=CC=CC=2)=C1 DFUTWTAXOYDQRR-UHFFFAOYSA-N 0.000 description 1
• YFMUACLZRVJOBK-UHFFFAOYSA-N 5-(2-phenylethynyl)thiophene-2-carbaldehyde Chemical compound S1C(C=O)=CC=C1C#CC1=CC=CC=C1 YFMUACLZRVJOBK-UHFFFAOYSA-N 0.000 description 1
• KLVCIHFXPHKSPD-UHFFFAOYSA-N 5-(trifluoromethyl)furan-2-carbaldehyde Chemical compound FC(F)(F)C1=CC=C(C=O)O1 KLVCIHFXPHKSPD-UHFFFAOYSA-N 0.000 description 1
• MMRIITDPKNWJQI-VOTSOKGWSA-N 5-[(e)-2-phenylethenyl]thiophene-3-carbaldehyde Chemical compound O=CC1=CSC(\C=C\C=2C=CC=CC=2)=C1 MMRIITDPKNWJQI-VOTSOKGWSA-N 0.000 description 1
• GFBVUFQNHLUCPX-UHFFFAOYSA-N 5-bromothiophene-2-carbaldehyde Chemical compound BrC1=CC=C(C=O)S1 GFBVUFQNHLUCPX-UHFFFAOYSA-N 0.000 description 1
• VWYFITBWBRVBSW-UHFFFAOYSA-N 5-chlorothiophene-2-carbaldehyde Chemical compound ClC1=CC=C(C=O)S1 VWYFITBWBRVBSW-UHFFFAOYSA-N 0.000 description 1
• SHNRXUWGUKDPMA-UHFFFAOYSA-N 5-formyl-2-furoic acid Chemical compound OC(=O)C1=CC=C(C=O)O1 SHNRXUWGUKDPMA-UHFFFAOYSA-N 0.000 description 1
• QJHLCUOJRLTPSI-UHFFFAOYSA-N 5-formyl-3-methylfuran-2-carboxylic acid Chemical compound CC=1C=C(C=O)OC=1C(O)=O QJHLCUOJRLTPSI-UHFFFAOYSA-N 0.000 description 1
• SEWHHLSEXYDKMQ-UHFFFAOYSA-N 5-iodothiophene-3-carbaldehyde Chemical compound IC1=CC(C=O)=CS1 SEWHHLSEXYDKMQ-UHFFFAOYSA-N 0.000 description 1
• CWDWFSXUQODZGW-UHFFFAOYSA-N 5-thiazolyl Chemical group [C]1=CN=CS1 CWDWFSXUQODZGW-UHFFFAOYSA-N 0.000 description 1
• 229930000680 A04AD01 - Scopolamine Natural products 0.000 description 1
• OZAIFHULBGXAKX-VAWYXSNFSA-N AIBN Substances N#CC(C)(C)\N=N\C(C)(C)C#N OZAIFHULBGXAKX-VAWYXSNFSA-N 0.000 description 1
• 206010000605 Acrophobia Diseases 0.000 description 1
• 102100035767 Adrenocortical dysplasia protein homolog Human genes 0.000 description 1
• 206010001497 Agitation Diseases 0.000 description 1
• 208000008811 Agoraphobia Diseases 0.000 description 1
• 206010001540 Akathisia Diseases 0.000 description 1
• 208000007848 Alcoholism Diseases 0.000 description 1
• 208000000103 Anorexia Nervosa Diseases 0.000 description 1
• 206010002652 Anorgasmia Diseases 0.000 description 1
• 208000036487 Arthropathies Diseases 0.000 description 1
• 201000001320 Atherosclerosis Diseases 0.000 description 1
• 208000008035 Back Pain Diseases 0.000 description 1
• 239000005711 Benzoic acid Substances 0.000 description 1
• OMPJBNCRMGITSC-UHFFFAOYSA-N Benzoylperoxide Chemical compound C=1C=CC=CC=1C(=O)OOC(=O)C1=CC=CC=C1 OMPJBNCRMGITSC-UHFFFAOYSA-N 0.000 description 1
• BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
• ZOXJGFHDIHLPTG-UHFFFAOYSA-N Boron Chemical compound [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 description 1
• 206010006550 Bulimia nervosa Diseases 0.000 description 1
• COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
• AUJKRWDRQZEARX-UHFFFAOYSA-N C1(=CC=CC=C1)CCC1=C(OC=C1)C=O Chemical compound C1(=CC=CC=C1)CCC1=C(OC=C1)C=O AUJKRWDRQZEARX-UHFFFAOYSA-N 0.000 description 1
• 102000004497 CCR2 Receptors Human genes 0.000 description 1
• 108010017312 CCR2 Receptors Proteins 0.000 description 1
• 206010006895 Cachexia Diseases 0.000 description 1
• OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
• OKTJSMMVPCPJKN-NJFSPNSNSA-N Carbon-14 Chemical compound [14C] OKTJSMMVPCPJKN-NJFSPNSNSA-N 0.000 description 1
• 208000002177 Cataract Diseases 0.000 description 1
• 241000700199 Cavia porcellus Species 0.000 description 1
• 206010008025 Cerebellar ataxia Diseases 0.000 description 1
• 206010008132 Cerebral thrombosis Diseases 0.000 description 1
• 206010008479 Chest Pain Diseases 0.000 description 1
• 201000006082 Chickenpox Diseases 0.000 description 1
• VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
• 101710178035 Chorismate synthase 2 Proteins 0.000 description 1
• 206010008874 Chronic Fatigue Syndrome Diseases 0.000 description 1
• 206010010071 Coma Diseases 0.000 description 1
• 206010010301 Confusion and disorientation Diseases 0.000 description 1
• 208000022540 Consciousness disease Diseases 0.000 description 1
• RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
• 229910021591 Copper(I) chloride Inorganic materials 0.000 description 1
• 229920000742 Cotton Polymers 0.000 description 1
• 238000006969 Curtius rearrangement reaction Methods 0.000 description 1
• XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
• 101710152694 Cysteine synthase 2 Proteins 0.000 description 1
• 125000000734 D-serino group Chemical group [H]N([H])[C@@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 1
• 208000020401 Depressive disease Diseases 0.000 description 1
• DYHSDKLCOJIUFX-UHFFFAOYSA-N Di-tert-butyl dicarbonate Substances CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 1
• 208000007342 Diabetic Nephropathies Diseases 0.000 description 1
• 206010012689 Diabetic retinopathy Diseases 0.000 description 1
• 208000012661 Dyskinesia Diseases 0.000 description 1
• 208000005189 Embolism Diseases 0.000 description 1
• PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
• 208000033962 Fontaine progeroid syndrome Diseases 0.000 description 1
• 102000005915 GABA Receptors Human genes 0.000 description 1
• 108010005551 GABA Receptors Proteins 0.000 description 1
• 101100295741 Gallus gallus COR4 gene Proteins 0.000 description 1
• 108010010803 Gelatin Proteins 0.000 description 1
• 208000011688 Generalised anxiety disease Diseases 0.000 description 1
• 102000007390 Glycogen Phosphorylase Human genes 0.000 description 1
• 108010046163 Glycogen Phosphorylase Proteins 0.000 description 1
• 206010019133 Hangover Diseases 0.000 description 1
• 208000032843 Hemorrhage Diseases 0.000 description 1
• STECJAGHUSJQJN-GAUPFVANSA-N Hyoscine Natural products C1([C@H](CO)C(=O)OC2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-GAUPFVANSA-N 0.000 description 1
• 208000035150 Hypercholesterolemia Diseases 0.000 description 1
• 206010051161 Hyperglucagonaemia Diseases 0.000 description 1
• 206010060378 Hyperinsulinaemia Diseases 0.000 description 1
• 208000031226 Hyperlipidaemia Diseases 0.000 description 1
• 206010020751 Hypersensitivity Diseases 0.000 description 1
• 206010020772 Hypertension Diseases 0.000 description 1
• 208000013016 Hypoglycemia Diseases 0.000 description 1
• XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 1
• 206010022489 Insulin Resistance Diseases 0.000 description 1
• 206010048620 Intracardiac thrombus Diseases 0.000 description 1
• 201000001429 Intracranial Thrombosis Diseases 0.000 description 1
• 208000015592 Involuntary movements Diseases 0.000 description 1
• 208000012659 Joint disease Diseases 0.000 description 1
• VLSMHEGGTFMBBZ-OOZYFLPDSA-M Kainate Chemical compound CC(=C)[C@H]1C[NH2+][C@H](C([O-])=O)[C@H]1CC([O-])=O VLSMHEGGTFMBBZ-OOZYFLPDSA-M 0.000 description 1
• YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 1
• 238000006000 Knoevenagel condensation reaction Methods 0.000 description 1
• 208000006264 Korsakoff syndrome Diseases 0.000 description 1
• 229930195714 L-glutamate Natural products 0.000 description 1
• 229910013596 LiOH—H2O Inorganic materials 0.000 description 1
• 240000005265 Lupinus mutabilis Species 0.000 description 1
• 235000008755 Lupinus mutabilis Nutrition 0.000 description 1
• 208000027382 Mental deterioration Diseases 0.000 description 1
• 206010027374 Mental impairment Diseases 0.000 description 1
• DUGOZIWVEXMGBE-UHFFFAOYSA-N Methylphenidate Chemical compound C=1C=CC=CC=1C(C(=O)OC)C1CCCCN1 DUGOZIWVEXMGBE-UHFFFAOYSA-N 0.000 description 1
• 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
• 208000019695 Migraine disease Diseases 0.000 description 1
• 208000016285 Movement disease Diseases 0.000 description 1
• JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 1
• STECJAGHUSJQJN-UHFFFAOYSA-N N-Methyl-scopolamin Natural products C1C(C2C3O2)N(C)C3CC1OC(=O)C(CO)C1=CC=CC=C1 STECJAGHUSJQJN-UHFFFAOYSA-N 0.000 description 1
• 239000007832 Na2SO4 Substances 0.000 description 1
• 206010028836 Neck pain Diseases 0.000 description 1
• 208000031264 Nerve root compression Diseases 0.000 description 1
• 244000061176 Nicotiana tabacum Species 0.000 description 1
• 235000002637 Nicotiana tabacum Nutrition 0.000 description 1
• 229910003849 O-Si Inorganic materials 0.000 description 1
• 208000021384 Obsessive-Compulsive disease Diseases 0.000 description 1
• 229910003873 O—P—O Inorganic materials 0.000 description 1
• 229910003872 O—Si Inorganic materials 0.000 description 1
• 206010033799 Paralysis Diseases 0.000 description 1
• 101150003085 Pdcl gene Proteins 0.000 description 1
• 206010034912 Phobia Diseases 0.000 description 1
• PIJVFDBKTWXHHD-UHFFFAOYSA-N Physostigmine Natural products C12=CC(OC(=O)NC)=CC=C2N(C)C2C1(C)CCN2C PIJVFDBKTWXHHD-UHFFFAOYSA-N 0.000 description 1
• GMZVRMREEHBGGF-UHFFFAOYSA-N Piracetam Chemical compound NC(=O)CN1CCCC1=O GMZVRMREEHBGGF-UHFFFAOYSA-N 0.000 description 1
• 239000004698 Polyethylene Substances 0.000 description 1
• 239000002202 Polyethylene glycol Substances 0.000 description 1
• ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
• 102000003946 Prolactin Human genes 0.000 description 1
• 108010057464 Prolactin Proteins 0.000 description 1
• 102000002067 Protein Subunits Human genes 0.000 description 1
• 108010001267 Protein Subunits Proteins 0.000 description 1
• 208000001431 Psychomotor Agitation Diseases 0.000 description 1
• WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 1
• 206010037660 Pyrexia Diseases 0.000 description 1
• 241000283984 Rodentia Species 0.000 description 1
• QCHFTSOMWOSFHM-UHFFFAOYSA-N SJ000285536 Natural products C1OC(=O)C(CC)C1CC1=CN=CN1C QCHFTSOMWOSFHM-UHFFFAOYSA-N 0.000 description 1
• 101100184046 Schizosaccharomyces pombe (strain 972 / ATCC 24843) mid1 gene Proteins 0.000 description 1
• 235000019095 Sechium edule Nutrition 0.000 description 1
• 206010039966 Senile dementia Diseases 0.000 description 1
• MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
• 201000001880 Sexual dysfunction Diseases 0.000 description 1
• 229910004298 SiO 2 Inorganic materials 0.000 description 1
• BLRPTPMANUNPDV-UHFFFAOYSA-N Silane Chemical compound [SiH4] BLRPTPMANUNPDV-UHFFFAOYSA-N 0.000 description 1
• XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
• 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
• 206010041243 Social avoidant behaviour Diseases 0.000 description 1
• 206010072005 Spinal pain Diseases 0.000 description 1
• 229920002472 Starch Polymers 0.000 description 1
• 206010042008 Stereotypy Diseases 0.000 description 1
• 208000006011 Stroke Diseases 0.000 description 1
• QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
• NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
• 241000282898 Sus scrofa Species 0.000 description 1
• 244000223014 Syzygium aromaticum Species 0.000 description 1
• 206010043118 Tardive Dyskinesia Diseases 0.000 description 1
• 208000001435 Thromboembolism Diseases 0.000 description 1
• 208000031674 Traumatic Acute Stress disease Diseases 0.000 description 1
• 206010044565 Tremor Diseases 0.000 description 1
• 108010039203 Tripeptidyl-Peptidase 1 Proteins 0.000 description 1
• 206010044688 Trisomy 21 Diseases 0.000 description 1
• YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 1
• 206010046980 Varicella Diseases 0.000 description 1
• 208000021017 Weight Gain Diseases 0.000 description 1
• CBMCZKMIOZYAHS-IHWYPQMZSA-N [(z)-prop-1-enyl]boronic acid Chemical compound C\C=C/B(O)O CBMCZKMIOZYAHS-IHWYPQMZSA-N 0.000 description 1
• WEVYAHXRMPXWCK-FIBGUPNXSA-N acetonitrile-d3 Chemical compound [2H]C([2H])([2H])C#N WEVYAHXRMPXWCK-FIBGUPNXSA-N 0.000 description 1
• 150000001252 acrylic acid derivatives Chemical class 0.000 description 1
• 208000026345 acute stress disease Diseases 0.000 description 1
• 230000010933 acylation Effects 0.000 description 1
• 238000005917 acylation reaction Methods 0.000 description 1
• 230000006978 adaptation Effects 0.000 description 1
• 230000003044 adaptive effect Effects 0.000 description 1
• 238000012382 advanced drug delivery Methods 0.000 description 1
• 230000007000 age related cognitive decline Effects 0.000 description 1
• 201000007930 alcohol dependence Diseases 0.000 description 1
• 150000001298 alcohols Chemical class 0.000 description 1
• 150000001335 aliphatic alkanes Chemical class 0.000 description 1
• 125000003282 alkyl amino group Chemical group 0.000 description 1
• 125000004414 alkyl thio group Chemical group 0.000 description 1
• 125000005237 alkyleneamino group Chemical group 0.000 description 1
• 125000005238 alkylenediamino group Chemical group 0.000 description 1
• 125000005530 alkylenedioxy group Chemical group 0.000 description 1
• 125000000304 alkynyl group Chemical group 0.000 description 1
• 208000026935 allergic disease Diseases 0.000 description 1
• HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
• 229910052782 aluminium Inorganic materials 0.000 description 1
• XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
• 125000003277 amino group Chemical group 0.000 description 1
• 229940025084 amphetamine Drugs 0.000 description 1
• 210000004727 amygdala Anatomy 0.000 description 1
• 230000000202 analgesic effect Effects 0.000 description 1
• 229940035676 analgesics Drugs 0.000 description 1
• 229960000793 aniracetam Drugs 0.000 description 1
• ZXNRTKGTQJPIJK-UHFFFAOYSA-N aniracetam Chemical compound C1=CC(OC)=CC=C1C(=O)N1C(=O)CCC1 ZXNRTKGTQJPIJK-UHFFFAOYSA-N 0.000 description 1
• 239000005557 antagonist Substances 0.000 description 1
• 239000000730 antalgic agent Substances 0.000 description 1
• 230000003502 anti-nociceptive effect Effects 0.000 description 1
• 239000001961 anticonvulsive agent Substances 0.000 description 1
• 229960003965 antiepileptics Drugs 0.000 description 1
• 239000003963 antioxidant agent Substances 0.000 description 1
• 229940111121 antirheumatic drug quinolines Drugs 0.000 description 1
• 230000036528 appetite Effects 0.000 description 1
• 235000019789 appetite Nutrition 0.000 description 1
• 230000009118 appropriate response Effects 0.000 description 1
• 206010003246 arthritis Diseases 0.000 description 1
• 125000004104 aryloxy group Chemical group 0.000 description 1
• YCOXTKKNXUZSKD-UHFFFAOYSA-N as-o-xylenol Natural products CC1=CC=C(O)C=C1C YCOXTKKNXUZSKD-UHFFFAOYSA-N 0.000 description 1
• 230000035045 associative learning Effects 0.000 description 1
• QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
• 239000003693 atypical antipsychotic agent Substances 0.000 description 1
• 229940127236 atypical antipsychotics Drugs 0.000 description 1
• RNOAANRGEYCUQZ-UHFFFAOYSA-N azido acetate Chemical compound CC(=O)ON=[N+]=[N-] RNOAANRGEYCUQZ-UHFFFAOYSA-N 0.000 description 1
• WURBFLDFSFBTLW-UHFFFAOYSA-N benzil Chemical group C=1C=CC=CC=1C(=O)C(=O)C1=CC=CC=C1 WURBFLDFSFBTLW-UHFFFAOYSA-N 0.000 description 1
• 150000008316 benzisoxazoles Chemical class 0.000 description 1
• 235000010233 benzoic acid Nutrition 0.000 description 1
• WXNOJTUTEXAZLD-UHFFFAOYSA-L benzonitrile;dichloropalladium Chemical compound Cl[Pd]Cl.N#CC1=CC=CC=C1.N#CC1=CC=CC=C1 WXNOJTUTEXAZLD-UHFFFAOYSA-L 0.000 description 1
• 235000019400 benzoyl peroxide Nutrition 0.000 description 1
• 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
• 238000002306 biochemical method Methods 0.000 description 1
• 125000000319 biphenyl-4-yl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 1
• 239000008280 blood Substances 0.000 description 1
• 210000004369 blood Anatomy 0.000 description 1
• 230000036765 blood level Effects 0.000 description 1
• 210000001218 blood-brain barrier Anatomy 0.000 description 1
• 230000037396 body weight Effects 0.000 description 1
• 238000009835 boiling Methods 0.000 description 1
• 210000000988 bone and bone Anatomy 0.000 description 1
• 230000005978 brain dysfunction Effects 0.000 description 1
• 125000001246 bromo group Chemical group Br* 0.000 description 1
• 239000006227 byproduct Substances 0.000 description 1
• 229910000024 caesium carbonate Inorganic materials 0.000 description 1
• 239000011575 calcium Substances 0.000 description 1
• 229910052791 calcium Inorganic materials 0.000 description 1
• 235000017663 capsaicin Nutrition 0.000 description 1
• 229960002504 capsaicin Drugs 0.000 description 1
• 239000004202 carbamide Substances 0.000 description 1
• 229960004424 carbon dioxide Drugs 0.000 description 1
• 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
• 125000002843 carboxylic acid group Chemical group 0.000 description 1
• 239000003054 catalyst Substances 0.000 description 1
• 206010007776 catatonia Diseases 0.000 description 1
• 125000002091 cationic group Chemical group 0.000 description 1
• 230000006727 cell loss Effects 0.000 description 1
• 230000002490 cerebral effect Effects 0.000 description 1
• 238000007385 chemical modification Methods 0.000 description 1
• 239000012069 chiral reagent Substances 0.000 description 1
• 125000001309 chloro group Chemical group Cl* 0.000 description 1
• FCYRSDMGOLYDHL-UHFFFAOYSA-N chloromethoxyethane Chemical compound CCOCCl FCYRSDMGOLYDHL-UHFFFAOYSA-N 0.000 description 1
• 230000001713 cholinergic effect Effects 0.000 description 1
• 230000000718 cholinopositive effect Effects 0.000 description 1
• 208000037976 chronic inflammation Diseases 0.000 description 1
• 208000037893 chronic inflammatory disorder Diseases 0.000 description 1
• 229940110456 cocoa butter Drugs 0.000 description 1
• 235000019868 cocoa butter Nutrition 0.000 description 1
• 239000002475 cognitive enhancer Substances 0.000 description 1
• 230000036992 cognitive tasks Effects 0.000 description 1
• 239000003086 colorant Substances 0.000 description 1
• 208000030251 communication disease Diseases 0.000 description 1
• 229940125810 compound 20 Drugs 0.000 description 1
• 239000012141 concentrate Substances 0.000 description 1
• 230000008602 contraction Effects 0.000 description 1
• 238000013270 controlled release Methods 0.000 description 1
• 230000001276 controlling effect Effects 0.000 description 1
• 238000007796 conventional method Methods 0.000 description 1
• 230000036461 convulsion Effects 0.000 description 1
• 229910052802 copper Inorganic materials 0.000 description 1
• 239000010949 copper Substances 0.000 description 1
• OXBLHERUFWYNTN-UHFFFAOYSA-M copper(I) chloride Chemical compound [Cu]Cl OXBLHERUFWYNTN-UHFFFAOYSA-M 0.000 description 1
• ORTQZVOHEJQUHG-UHFFFAOYSA-L copper(II) chloride Chemical compound Cl[Cu]Cl ORTQZVOHEJQUHG-UHFFFAOYSA-L 0.000 description 1
• GBRBMTNGQBKBQE-UHFFFAOYSA-L copper;diiodide Chemical compound I[Cu]I GBRBMTNGQBKBQE-UHFFFAOYSA-L 0.000 description 1
• 230000008878 coupling Effects 0.000 description 1
• 238000010168 coupling process Methods 0.000 description 1
• 238000005859 coupling reaction Methods 0.000 description 1
• WZHCOOQXZCIUNC-UHFFFAOYSA-N cyclandelate Chemical compound C1C(C)(C)CC(C)CC1OC(=O)C(O)C1=CC=CC=C1 WZHCOOQXZCIUNC-UHFFFAOYSA-N 0.000 description 1
• 125000000392 cycloalkenyl group Chemical group 0.000 description 1
• 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
• 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
• 125000004210 cyclohexylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
• 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
• WLVKDFJTYKELLQ-UHFFFAOYSA-N cyclopropylboronic acid Chemical compound OB(O)C1CC1 WLVKDFJTYKELLQ-UHFFFAOYSA-N 0.000 description 1
• 125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 description 1
• 230000002939 deleterious effect Effects 0.000 description 1
• 230000001419 dependent effect Effects 0.000 description 1
• 230000005595 deprotonation Effects 0.000 description 1
• 238000010537 deprotonation reaction Methods 0.000 description 1
• 238000011161 development Methods 0.000 description 1
• 230000018109 developmental process Effects 0.000 description 1
• 229940119751 dextroamphetamine sulfate Drugs 0.000 description 1
• 208000033679 diabetic kidney disease Diseases 0.000 description 1
• QZHDNICXKYAEKK-UHFFFAOYSA-N diazomethyl(trimethyl)silane;hexane Chemical class CCCCCC.C[Si](C)(C)C=[N+]=[N-] QZHDNICXKYAEKK-UHFFFAOYSA-N 0.000 description 1
• JAEHVOBOWZVTFO-UHFFFAOYSA-N diazonio-[3-ethoxy-1-(4-fluorofuran-2-yl)-3-oxoprop-1-en-2-yl]azanide Chemical compound CCOC(=O)C(N=[N+]=[N-])=CC1=CC(F)=CO1 JAEHVOBOWZVTFO-UHFFFAOYSA-N 0.000 description 1
• WBKFWQBXFREOFH-UHFFFAOYSA-N dichloromethane;ethyl acetate Chemical compound ClCCl.CCOC(C)=O WBKFWQBXFREOFH-UHFFFAOYSA-N 0.000 description 1
• 229910001873 dinitrogen Inorganic materials 0.000 description 1
• 230000008034 disappearance Effects 0.000 description 1
• 239000002270 dispersing agent Substances 0.000 description 1
• 239000006185 dispersion Substances 0.000 description 1
• 238000004821 distillation Methods 0.000 description 1
• 238000009826 distribution Methods 0.000 description 1
• 229960003530 donepezil Drugs 0.000 description 1
• 229960003135 donepezil hydrochloride Drugs 0.000 description 1
• XWAIAVWHZJNZQQ-UHFFFAOYSA-N donepezil hydrochloride Chemical compound [H+].[Cl-].O=C1C=2C=C(OC)C(OC)=CC=2CC1CC(CC1)CCN1CC1=CC=CC=C1 XWAIAVWHZJNZQQ-UHFFFAOYSA-N 0.000 description 1
• 239000002552 dosage form Substances 0.000 description 1
• 238000012377 drug delivery Methods 0.000 description 1
• 206010013663 drug dependence Diseases 0.000 description 1
• 239000003596 drug target Substances 0.000 description 1
• 238000003255 drug test Methods 0.000 description 1
• 235000006694 eating habits Nutrition 0.000 description 1
• 230000002500 effect on skin Effects 0.000 description 1
• 230000002996 emotional effect Effects 0.000 description 1
• 239000000839 emulsion Substances 0.000 description 1
• 239000006274 endogenous ligand Substances 0.000 description 1
• 230000002255 enzymatic effect Effects 0.000 description 1
• 230000002397 epileptogenic effect Effects 0.000 description 1
• 235000019441 ethanol Nutrition 0.000 description 1
• YFXCNIVBAVFOBX-UHFFFAOYSA-N ethenylboronic acid Chemical compound OB(O)C=C YFXCNIVBAVFOBX-UHFFFAOYSA-N 0.000 description 1
• 125000005745 ethoxymethyl group Chemical group [H]C([H])([H])C([H])([H])OC([H])([H])* 0.000 description 1
• QPMJENKZJUFOON-PLNGDYQASA-N ethyl (z)-3-chloro-2-cyano-4,4,4-trifluorobut-2-enoate Chemical compound CCOC(=O)C(\C#N)=C(/Cl)C(F)(F)F QPMJENKZJUFOON-PLNGDYQASA-N 0.000 description 1
• XHELTWFUFRUTPH-UHFFFAOYSA-N ethyl 2-azido-3-(5-fluorothiophen-2-yl)prop-2-enoate Chemical compound CCOC(=O)C(N=[N+]=[N-])=CC1=CC=C(F)S1 XHELTWFUFRUTPH-UHFFFAOYSA-N 0.000 description 1
• DBYWTQSBIHSINZ-UHFFFAOYSA-N ethyl 2-azido-3-(5-methylthiophen-2-yl)prop-2-enoate Chemical compound CCOC(=O)C(N=[N+]=[N-])=CC1=CC=C(C)S1 DBYWTQSBIHSINZ-UHFFFAOYSA-N 0.000 description 1
• BSIIENSVDCHCBF-UHFFFAOYSA-N ethyl 2-chloro-4h-furo[3,2-b]pyrrole-5-carboxylate Chemical compound O1C(Cl)=CC2=C1C=C(C(=O)OCC)N2 BSIIENSVDCHCBF-UHFFFAOYSA-N 0.000 description 1
• IXGBRRWUBAVAFD-UHFFFAOYSA-N ethyl 2-fluoro-4h-furo[3,2-b]pyrrole-5-carboxylate Chemical compound O1C(F)=CC2=C1C=C(C(=O)OCC)N2 IXGBRRWUBAVAFD-UHFFFAOYSA-N 0.000 description 1
• OOWDCGMCFQICNN-CMDGGOBGSA-N ethyl 3-[(e)-2-phenylethenyl]-4h-furo[3,2-b]pyrrole-5-carboxylate Chemical compound C1=2NC(C(=O)OCC)=CC=2OC=C1\C=C\C1=CC=CC=C1 OOWDCGMCFQICNN-CMDGGOBGSA-N 0.000 description 1
• MHYCRLGKOZWVEF-UHFFFAOYSA-N ethyl acetate;hydrate Chemical compound O.CCOC(C)=O MHYCRLGKOZWVEF-UHFFFAOYSA-N 0.000 description 1
• 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
• 230000000763 evoking effect Effects 0.000 description 1
• 230000010326 executive functioning Effects 0.000 description 1
• 238000002474 experimental method Methods 0.000 description 1
• 230000008921 facial expression Effects 0.000 description 1
• 208000033699 familial Guillain-Barre syndrome Diseases 0.000 description 1
• 230000014061 fear response Effects 0.000 description 1
• 239000012065 filter cake Substances 0.000 description 1
• 239000000796 flavoring agent Substances 0.000 description 1
• 235000013355 food flavoring agent Nutrition 0.000 description 1
• 210000001061 forehead Anatomy 0.000 description 1
• 229940004296 formula 21 Drugs 0.000 description 1
• 125000000524 functional group Chemical group 0.000 description 1
• 229960003692 gamma aminobutyric acid Drugs 0.000 description 1
• BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 1
• 238000002290 gas chromatography-mass spectrometry Methods 0.000 description 1
• 239000008273 gelatin Substances 0.000 description 1
• 229920000159 gelatin Polymers 0.000 description 1
• 235000019322 gelatine Nutrition 0.000 description 1
• 235000011852 gelatine desserts Nutrition 0.000 description 1
• 208000029364 generalized anxiety disease Diseases 0.000 description 1
• 230000002068 genetic effect Effects 0.000 description 1
• 239000012362 glacial acetic acid Substances 0.000 description 1
• 235000011187 glycerol Nutrition 0.000 description 1
• 150000002334 glycols Chemical class 0.000 description 1
• 239000003979 granulating agent Substances 0.000 description 1
• 229940093915 gynecological organic acid Drugs 0.000 description 1
• 125000005843 halogen group Chemical group 0.000 description 1
• 238000010438 heat treatment Methods 0.000 description 1
• 125000004366 heterocycloalkenyl group Chemical group 0.000 description 1
• 125000004415 heterocyclylalkyl group Chemical group 0.000 description 1
• 239000008241 heterogeneous mixture Substances 0.000 description 1
• 230000000971 hippocampal effect Effects 0.000 description 1
• 239000008240 homogeneous mixture Substances 0.000 description 1
• 150000002430 hydrocarbons Chemical group 0.000 description 1
• 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
• 238000005984 hydrogenation reaction Methods 0.000 description 1
• 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 1
• 230000035880 hyperglucagonemia Effects 0.000 description 1
• 230000003451 hyperinsulinaemic effect Effects 0.000 description 1
• 201000008980 hyperinsulinism Diseases 0.000 description 1
• 230000009610 hypersensitivity Effects 0.000 description 1
• 208000006575 hypertriglyceridemia Diseases 0.000 description 1
• 150000002460 imidazoles Chemical group 0.000 description 1
• 208000026278 immune system disease Diseases 0.000 description 1
• 239000012535 impurity Substances 0.000 description 1
• 238000012623 in vivo measurement Methods 0.000 description 1
• 238000010348 incorporation Methods 0.000 description 1
• APFVFJFRJDLVQX-UHFFFAOYSA-N indium atom Chemical compound [In] APFVFJFRJDLVQX-UHFFFAOYSA-N 0.000 description 1
• 239000003701 inert diluent Substances 0.000 description 1
• 208000015181 infectious disease Diseases 0.000 description 1
• 230000008595 infiltration Effects 0.000 description 1
• 238000001764 infiltration Methods 0.000 description 1
• 206010022437 insomnia Diseases 0.000 description 1
• 208000001286 intracranial vasospasm Diseases 0.000 description 1
• 238000007918 intramuscular administration Methods 0.000 description 1
• 239000011630 iodine Substances 0.000 description 1
• 229940044173 iodine-125 Drugs 0.000 description 1
• SNHMUERNLJLMHN-UHFFFAOYSA-N iodobenzene Chemical compound IC1=CC=CC=C1 SNHMUERNLJLMHN-UHFFFAOYSA-N 0.000 description 1
• 230000003447 ipsilateral effect Effects 0.000 description 1
• 230000002427 irreversible effect Effects 0.000 description 1
• 239000002085 irritant Substances 0.000 description 1
• 231100000021 irritant Toxicity 0.000 description 1
• OWFXIOWLTKNBAP-UHFFFAOYSA-N isoamyl nitrite Chemical compound CC(C)CCON=O OWFXIOWLTKNBAP-UHFFFAOYSA-N 0.000 description 1
• 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
• ULYZAYCEDJDHCC-UHFFFAOYSA-N isopropyl chloride Chemical compound CC(C)Cl ULYZAYCEDJDHCC-UHFFFAOYSA-N 0.000 description 1
• 150000003854 isothiazoles Chemical group 0.000 description 1
• 230000000155 isotopic effect Effects 0.000 description 1
• 150000002545 isoxazoles Chemical group 0.000 description 1
• 229960003299 ketamine Drugs 0.000 description 1
• 150000004715 keto acids Chemical class 0.000 description 1
• 230000003907 kidney function Effects 0.000 description 1
• 201000010901 lateral sclerosis Diseases 0.000 description 1
• 230000000670 limiting effect Effects 0.000 description 1
• GLXDVVHUTZTUQK-UHFFFAOYSA-M lithium;hydroxide;hydrate Chemical compound [Li+].O.[OH-] GLXDVVHUTZTUQK-UHFFFAOYSA-M 0.000 description 1
• 230000003908 liver function Effects 0.000 description 1
• 230000007787 long-term memory Effects 0.000 description 1
• 159000000003 magnesium salts Chemical class 0.000 description 1
• 230000036210 malignancy Effects 0.000 description 1
• 210000005171 mammalian brain Anatomy 0.000 description 1
• 238000005259 measurement Methods 0.000 description 1
• 238000002483 medication Methods 0.000 description 1
• 230000007087 memory ability Effects 0.000 description 1
• 230000005056 memory consolidation Effects 0.000 description 1
• 230000003340 mental effect Effects 0.000 description 1
• HRDXJKGNWSUIBT-UHFFFAOYSA-N methoxybenzene Chemical group [CH2]OC1=CC=CC=C1 HRDXJKGNWSUIBT-UHFFFAOYSA-N 0.000 description 1
• 229960001344 methylphenidate Drugs 0.000 description 1
• 239000008108 microcrystalline cellulose Substances 0.000 description 1
• 229940016286 microcrystalline cellulose Drugs 0.000 description 1
• 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
• 150000007522 mineralic acids Chemical class 0.000 description 1
• 238000002156 mixing Methods 0.000 description 1
• 239000007932 molded tablet Substances 0.000 description 1
• 125000006682 monohaloalkyl group Chemical group 0.000 description 1
• 125000004572 morpholin-3-yl group Chemical group N1C(COCC1)* 0.000 description 1
• 230000037023 motor activity Effects 0.000 description 1
• 208000005264 motor neuron disease Diseases 0.000 description 1
• 230000003551 muscarinic effect Effects 0.000 description 1
• 208000013465 muscle pain Diseases 0.000 description 1
• 230000017311 musculoskeletal movement, spinal reflex action Effects 0.000 description 1
• 125000003136 n-heptyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
• 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
• 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
• 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
• 150000002790 naphthalenes Chemical class 0.000 description 1
• 230000010807 negative regulation of binding Effects 0.000 description 1
• 210000004126 nerve fiber Anatomy 0.000 description 1
• 230000007383 nerve stimulation Effects 0.000 description 1
• 230000001537 neural effect Effects 0.000 description 1
• 210000004498 neuroglial cell Anatomy 0.000 description 1
• 239000002858 neurotransmitter agent Substances 0.000 description 1
• 230000001777 nootropic effect Effects 0.000 description 1
• 238000012587 nuclear overhauser effect experiment Methods 0.000 description 1
• 230000003287 optical effect Effects 0.000 description 1
• 239000006186 oral dosage form Substances 0.000 description 1
• 210000000056 organ Anatomy 0.000 description 1
• 150000007524 organic acids Chemical class 0.000 description 1
• 235000005985 organic acids Nutrition 0.000 description 1
• 150000002916 oxazoles Chemical group 0.000 description 1
• 239000007800 oxidant agent Substances 0.000 description 1
• 229960001227 oxiracetam Drugs 0.000 description 1
• IHLAQQPQKRMGSS-UHFFFAOYSA-N oxiracetam Chemical compound NC(=O)CN1CC(O)CC1=O IHLAQQPQKRMGSS-UHFFFAOYSA-N 0.000 description 1
• 239000001301 oxygen Substances 0.000 description 1
• 125000001037 p-tolyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])([H])[H] 0.000 description 1
• 230000008058 pain sensation Effects 0.000 description 1
• 239000004031 partial agonist Substances 0.000 description 1
• 230000007170 pathology Effects 0.000 description 1
• 230000037361 pathway Effects 0.000 description 1
• 210000000578 peripheral nerve Anatomy 0.000 description 1
• 210000001428 peripheral nervous system Anatomy 0.000 description 1
• 210000002856 peripheral neuron Anatomy 0.000 description 1
• 150000002978 peroxides Chemical class 0.000 description 1
• 238000011170 pharmaceutical development Methods 0.000 description 1
• 239000002831 pharmacologic agent Substances 0.000 description 1
• 230000000144 pharmacologic effect Effects 0.000 description 1
• 238000001050 pharmacotherapy Methods 0.000 description 1
• JTJMJGYZQZDUJJ-UHFFFAOYSA-N phencyclidine Chemical compound C1CCCCN1C1(C=2C=CC=CC=2)CCCCC1 JTJMJGYZQZDUJJ-UHFFFAOYSA-N 0.000 description 1
• 235000011007 phosphoric acid Nutrition 0.000 description 1
• 150000003016 phosphoric acids Chemical class 0.000 description 1
• 230000000704 physical effect Effects 0.000 description 1
• 230000004962 physiological condition Effects 0.000 description 1
• 230000035790 physiological processes and functions Effects 0.000 description 1
• PIJVFDBKTWXHHD-HIFRSBDPSA-N physostigmine Chemical compound C12=CC(OC(=O)NC)=CC=C2N(C)[C@@H]2[C@@]1(C)CCN2C PIJVFDBKTWXHHD-HIFRSBDPSA-N 0.000 description 1
• 229960001697 physostigmine Drugs 0.000 description 1
• 229960001416 pilocarpine Drugs 0.000 description 1
• 125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
• 125000004483 piperidin-3-yl group Chemical group N1CC(CCC1)* 0.000 description 1
• 229960004526 piracetam Drugs 0.000 description 1
• 239000002798 polar solvent Substances 0.000 description 1
• 125000006684 polyhaloalkyl group Polymers 0.000 description 1
• 239000011591 potassium Substances 0.000 description 1
• 229910052700 potassium Inorganic materials 0.000 description 1
• 239000012286 potassium permanganate Substances 0.000 description 1
• 230000003389 potentiating effect Effects 0.000 description 1
• 239000003755 preservative agent Substances 0.000 description 1
• 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
• 230000007425 progressive decline Effects 0.000 description 1
• 229940097325 prolactin Drugs 0.000 description 1
• 230000002035 prolonged effect Effects 0.000 description 1
• TVDSBUOJIPERQY-UHFFFAOYSA-N prop-2-yn-1-ol Chemical compound OCC#C TVDSBUOJIPERQY-UHFFFAOYSA-N 0.000 description 1
• 125000004368 propenyl group Chemical group C(=CC)* 0.000 description 1
• 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 1
• 230000001107 psychogenic effect Effects 0.000 description 1
• 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 1
• 125000003373 pyrazinyl group Chemical group 0.000 description 1
• 150000003217 pyrazoles Chemical group 0.000 description 1
• 125000005344 pyridylmethyl group Chemical group [H]C1=C([H])C([H])=C([H])C(=N1)C([H])([H])* 0.000 description 1
• WRHZVMBBRYBTKZ-UHFFFAOYSA-N pyrrole-2-carboxylic acid Chemical compound OC(=O)C1=CC=CN1 WRHZVMBBRYBTKZ-UHFFFAOYSA-N 0.000 description 1
• GZTPJDLYPMPRDF-UHFFFAOYSA-N pyrrolo[3,2-c]pyrazole Chemical compound N1=NC2=CC=NC2=C1 GZTPJDLYPMPRDF-UHFFFAOYSA-N 0.000 description 1
• 150000003248 quinolines Chemical class 0.000 description 1
• 238000001959 radiotherapy Methods 0.000 description 1
• 230000003252 repetitive effect Effects 0.000 description 1
• 238000009256 replacement therapy Methods 0.000 description 1
• 238000011160 research Methods 0.000 description 1
• 230000002441 reversible effect Effects 0.000 description 1
• 206010039073 rheumatoid arthritis Diseases 0.000 description 1
• 244000195895 saibo Species 0.000 description 1
• 239000000523 sample Substances 0.000 description 1
• 229930195734 saturated hydrocarbon Natural products 0.000 description 1
• 210000004761 scalp Anatomy 0.000 description 1
• STECJAGHUSJQJN-FWXGHANASA-N scopolamine Chemical compound C1([C@@H](CO)C(=O)O[C@H]2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-FWXGHANASA-N 0.000 description 1
• 229960002646 scopolamine Drugs 0.000 description 1
• 208000012672 seasonal affective disease Diseases 0.000 description 1
• 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
• 230000035807 sensation Effects 0.000 description 1
• 230000001953 sensory effect Effects 0.000 description 1
• 230000009155 sensory pathway Effects 0.000 description 1
• 229940076279 serotonin Drugs 0.000 description 1
• 210000002966 serum Anatomy 0.000 description 1
• 231100000872 sexual dysfunction Toxicity 0.000 description 1
• 238000007493 shaping process Methods 0.000 description 1
• 230000006403 short-term memory Effects 0.000 description 1
• 229910000077 silane Inorganic materials 0.000 description 1
• 239000010703 silicon Substances 0.000 description 1
• 230000005586 smoking cessation Effects 0.000 description 1
• 230000000392 somatic effect Effects 0.000 description 1
• 208000027765 speech disease Diseases 0.000 description 1
• 210000000273 spinal nerve root Anatomy 0.000 description 1
• 235000019698 starch Nutrition 0.000 description 1
• 230000000638 stimulation Effects 0.000 description 1
• 229960001052 streptozocin Drugs 0.000 description 1
• 238000007920 subcutaneous administration Methods 0.000 description 1
• 235000000346 sugar Nutrition 0.000 description 1
• 150000008163 sugars Chemical class 0.000 description 1
• 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 1
• 239000011593 sulfur Substances 0.000 description 1
• 239000000829 suppository Substances 0.000 description 1
• 239000000375 suspending agent Substances 0.000 description 1
• 230000002889 sympathetic effect Effects 0.000 description 1
• 210000000225 synapse Anatomy 0.000 description 1
• 230000003956 synaptic plasticity Effects 0.000 description 1
• 229960001685 tacrine Drugs 0.000 description 1
• 229960003565 tacrine hydrochloride Drugs 0.000 description 1
• 230000002123 temporal effect Effects 0.000 description 1
• MFPWEWYKQYMWRO-UHFFFAOYSA-N tert-butyl carboxy carbonate Chemical compound CC(C)(C)OC(=O)OC(O)=O MFPWEWYKQYMWRO-UHFFFAOYSA-N 0.000 description 1
• ILMRJRBKQSSXGY-UHFFFAOYSA-N tert-butyl(dimethyl)silicon Chemical compound C[Si](C)C(C)(C)C ILMRJRBKQSSXGY-UHFFFAOYSA-N 0.000 description 1
• VTORJPDWMOIOIQ-UHFFFAOYSA-N tert-butyl(diphenyl)silane Chemical compound C=1C=CC=CC=1[SiH](C(C)(C)C)C1=CC=CC=C1 VTORJPDWMOIOIQ-UHFFFAOYSA-N 0.000 description 1
• ZUNINWFVODGKGI-UHFFFAOYSA-N tert-butyl-[(4-fluorofuran-2-yl)methoxy]-dimethylsilane Chemical compound CC(C)(C)[Si](C)(C)OCC1=CC(F)=CO1 ZUNINWFVODGKGI-UHFFFAOYSA-N 0.000 description 1
• HWZBGYLRAHZQPA-UHFFFAOYSA-N tert-butyl-[(4-fluorothiophen-2-yl)methoxymethyl]-diphenylsilane Chemical compound C=1C=CC=CC=1[Si](C=1C=CC=CC=1)(C(C)(C)C)COCC1=CC(F)=CS1 HWZBGYLRAHZQPA-UHFFFAOYSA-N 0.000 description 1
• MHYGQXWCZAYSLJ-UHFFFAOYSA-N tert-butyl-chloro-diphenylsilane Chemical compound C=1C=CC=CC=1[Si](Cl)(C(C)(C)C)C1=CC=CC=C1 MHYGQXWCZAYSLJ-UHFFFAOYSA-N 0.000 description 1
• BCNZYOJHNLTNEZ-UHFFFAOYSA-N tert-butyldimethylsilyl chloride Chemical compound CC(C)(C)[Si](C)(C)Cl BCNZYOJHNLTNEZ-UHFFFAOYSA-N 0.000 description 1
• 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
• 229940124597 therapeutic agent Drugs 0.000 description 1
• 238000011287 therapeutic dose Methods 0.000 description 1
• 239000002562 thickening agent Substances 0.000 description 1
• 150000003568 thioethers Chemical class 0.000 description 1
• 150000003573 thiols Chemical class 0.000 description 1
• 230000003867 tiredness Effects 0.000 description 1
• 208000016255 tiredness Diseases 0.000 description 1
• 208000037816 tissue injury Diseases 0.000 description 1
• 208000004371 toothache Diseases 0.000 description 1
• 238000011200 topical administration Methods 0.000 description 1
• 238000007070 tosylation reaction Methods 0.000 description 1
• 239000003053 toxin Substances 0.000 description 1
• 238000012549 training Methods 0.000 description 1
• 230000009898 traumatic memory Effects 0.000 description 1
• 210000003901 trigeminal nerve Anatomy 0.000 description 1
• 230000001960 triggered effect Effects 0.000 description 1
• 125000000026 trimethylsilyl group Chemical group [H]C([H])([H])[Si]([*])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
• 229910052722 tritium Inorganic materials 0.000 description 1
• 230000001228 trophic effect Effects 0.000 description 1
• 238000005292 vacuum distillation Methods 0.000 description 1
• 230000001457 vasomotor Effects 0.000 description 1
• 210000001835 viscera Anatomy 0.000 description 1
• 230000031836 visual learning Effects 0.000 description 1
• 238000012800 visualization Methods 0.000 description 1
• 235000012431 wafers Nutrition 0.000 description 1
• 230000004584 weight gain Effects 0.000 description 1
• 235000019786 weight gain Nutrition 0.000 description 1
• 150000003738 xylenes Chemical class 0.000 description 1